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ABSTRACT 
 
Studies of bone density and diabetes have relatively strong evidence to suggest that type 1 
diabetes has negative impacts on bone mass density; however, there seems to be more 
discrepancy in skeletal effects of type 2 diabetes. While many studies have shown normal to high 
BMD values in individuals with type 2 diabetes, some have found low BMD values. We studied 
the relationship between diabetes-related variables and bone health status, specifically 
osteoporosis, by examining heel ultrasound and genetic markers. The objective of this study was 
to compare the bone mass density (BMD) and vitamin D receptor (VDR) gene marker of adult 
men and women with pre-, type 1 and type 2 diabetes (n=54). Subjects were recruited from 
faculty, staff and students of the University of Illinois at Urbana-Champaign, as well as 
participants from the Senior High Rise DM Outreach groups from Champaign-Urbana Public 
Health Department. Anthropometric measurements including height, weight, wrist, waist and hip 
circumferences were taken. Participants completed a self-administered questionnaire on 
demographics, diabetes status, lifestyles and health behaviors, physical activity, history of falling 
and bone fracture, current status and/or history of medical conditions and medication use, family 
history of diabetes and bone health-related diseases, and female reproductive history. Heel 
ultrasound (Hologic Sahara) was measured for bone analysis (n=52). Saliva samples were 
collected for DNA genotyping (n=50) and only analyzed for the VDR gene marker of 
Caucasian/white ethnic group (n=45). Among the 54 subjects, mean age was 62 years (27-86 
years) and median for duration of diabetes was 7 years (0.08-50 years). The majority of 
participants were white/Caucasian women with college/professional degree, who had type 2 
diabetes, were not on insulin and had diabetes for 7 or more years. Bone mineral density was 
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lower in subjects with type 1 diabetes compared to those with type 2 diabetes, but this difference 
lacked statistical significance. However, adjusting for age resulted in lower BMD and T-score 
values in individuals with type 1 diabetes as well as higher T-scores in those with type 2 
diabetes. Odds ratio of high BMD values were about 14.5 times greater in subjects with type 2 
diabetes than those with type 1 diabetes, which increased after adjustment for BMI. Univariate 
analysis detected significant associations for low bone mass density with age, current status 
and/or history of cancer, current use and/or history of any type of bone medication intake, 
menopause in females, and moderate physical activity in the past 7 days. Multiple regression 
model showed that African-American ethnicity, calcium/vitamin D supplement use, family 
history of loss of height, current status and/or history of osteoporosis, and menopause in females 
were significant predictors of low bone mass density. No statistically significant association was 
found between VDR genotype and bone mass density. Only age, duration of diabetes and 
menopause were significant independent risk factors for low BMD, but VDR genotype or VDR 
polymorphism were not associated with an increased risk for low BMD. In conclusion, 
additional research is needed to understand the link between BMD, diabetes status and VDR 
genetic marker.  
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CHAPTER 1 
INTRODUCTION 
 
Bone Function: 
Bone is a highly specialized and dynamic tissue which represents about 15% to 17% of total 
body weight (Ott, 1998). It has a variety of different functions including mechanical, 
hematological and chemical properties. The mechanical function of the bone consists of 
providing the structural framework that supports the softer tissues and provides sites of 
attachment for most skeletal muscles and tendons. In addition, this framework helps with the 
protection of internal organs including brain, thoracic and pelvic organs from damage induced by 
external mechanical forces. Due to attachment of bones to skeletal muscles, this rigid structure 
could assist in body movements during muscle contractions (Fanghänel et al, 2006; Brandi, 
2009). Bone’s hematological function consists of the ability of the red bone marrow to produce 
and store blood cells.  Red bone marrow is a functionally active hematopoietic composite found 
within the marrow cavities in bones of the extremities of all newborn mammals which supports 
hematopoiesis. As age increases, this hematopoietic microenvironment gradually converts into 
mesenchymal tissue that consists mainly of adipose cells which accumulate lipids, and a few 
hematopoietic cells with loss of ability to support blood generation. This new composite is 
referred to as yellow or fatty bone marrow which can help the bone in serving as an important 
chemical energy reserve at older ages. Yellow bone marrow can also be converted to red bone 
marrow at times of severe anemia (Gurevitch et al, 2009). The chemical property of the bone 
tissue also involves storage of several minerals including calcium and phosphorus, which 
2 
 
contributes to calcium metabolism and homeostasis. Bones contain 99% of the total body 
calcium and 90% of the body phosphorus (Ott, 1998, Brandi, 2009). 
 
Bone Structure: 
The above-mentioned bone functions are possible only due to the explicit bone structure. As a 
connective tissue, the microstructure of the bone consists of both organic and inorganic 
compounds, which comprise about 35% and 65% of the bone dry weight, respectively (Chan et 
al, 2002). The organic component represents the flexible and tough extracellular matrix and is 
composed of 95% type 1 collagen fibers which account for the high elasticity of bones, and 5% 
proteoglycans and several noncollagenous proteins. The rigid inorganic constituent of bone 
imbeds within this collagen matrix and is mainly composed of calcium phosphate salts which are 
deposited in the form of a mineral referred to as hydroxyapatite (Brandi, 2009). The chemical 
formula for hydroxyapatite crystals consists of hydroxyl ions as well as 5:3 ratio of calcium to 
phosphate molecules (Ott, 1998).  
In particular, both the collagen fibers and the calcium salts provide the bone structural strength 
and rigidity. The calcium salts are responsible for the great compressional strength of bones (the 
strength to endure squeezing forces), while collagen fibers account for the bone significant 
tensile strength (the strength to endure stretching forces). However, bones often lack a high level 
of torsional strength (the strength to endure twisting). Thus, most bone fractures occur as a result 
of torsional forces (Brandi, 2009). 
Macroscopically, there are two main types of bones in the body: trabecular (cancellous) and 
cortical (compact). Trabecular or cancellous bone has a highly porous structure and is mainly 
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concentrated at the ends of long bones such as the femur, tibia and fibula and at the inner parts of 
flat bones in vertebral bodies and pelvis (Ott, 1998; Brandi, 2009). Although trabecular bone 
accounts for only about 20% of all bone mass, it accounts for most of the bone volume (Ott, 
1998). Trabecular bone has a microstructure of struts or trabeculae which are arranged in a three-
dimensional open porous configuration that form a honeycomb-like pattern. The pores consist of 
both yellow bone marrow and red bone marrow which are responsible for bone adiposity and 
production of the blood cells including erythrocytes, platelets and leukocytes, respectively (Ott, 
1998). This microstructure gives directionality as well as mechanical stiffness and strength to the 
bone. 
Cortical or compact bone comprises about 80% of the body skeleton and is primarily found in 
the shaft of long bones such as the humerus, ulna and radius and the outer shell of flat bones 
including cranial bones, sternum and scapulae (Ott, 1998; Brandi, 2009). Due to its densely 
packed calcified collagen fibers, cortical bone has a much more rigid structure than trabecular 
bone. The microscopic structure of cortical bone consists of units referred to as haversian 
systems which are organized into concentric layers around an extensive longitudinal network of 
the central haversian canals termed canaliculi. Containing the bone extracellular fluid, canaliculi 
are filled with blood vessels which are responsible for nourishing the inner part of the bone (Ott, 
1998; Brandi, 2009).   
At the outer surface of compact bones the bone is completely enclosed by a fibrous structure 
called the periosteum. Penetration of bone by Sharpey’s fibers from periosteum serves to anchor 
it to the bone. Endosteum is the inner membraneous sheath that lines haversian canals and the 
inner surface of the marrow cavity. Both periosteum and endosteum contain blood vessels that 
nourish the bone cells (Brandi, 2009). 
4 
 
The above-mentioned structural differences account for the diverse functions of the cortical and 
trabecular bones. The relative proportion of the skeletal site localization of these two types of 
bone varies significantly depending on the functional demand for strength and weight. Although 
relatively lighter in weight, trabecular bone has considerable tensile strength and weight-bearing 
properties than the cortical bone, since the ends of long bones are subjected to the greatest forces 
of compression. Additionally, the turnover rate is three to four times higher in trabecular bone 
due to the larger surface area which makes it more metabolically active. These properties not 
only make the trabecular bones more likely to receive physical stress and become more 
susceptible to fractures, but also more likely to show faster signs of response to therapy (Ott, 
1998; Brandi, 2009).  
 
Bone Cells: 
There are typically four different types of bone cells: osteoprogenitor or lining cells, osteoblasts, 
osteocytes, and osteoclasts. Osteoprogenitor cells, osteoblasts and osteocytes derive from 
mesenchymal cell origin, whereas osteoclasts originate from a monocyte-macrophage linage of 
hematopoietic cells (Manolagas, 2000). 
Osteoprogenitor or lining cells are precursors of osteoblasts. These are undifferentiated cells 
which have the capacity for mitosis, resemble fibroblasts in structure, and line the entire bone 
surfaces. They can be proliferated into osteoblasts to participate in the initiation of bone 
remodeling (Manolagas, 2000; Pignolo et al, 2010). 
Osteoblasts, the bone-forming cells, are responsible for the formation of bone extracellular 
matrix and its subsequent mineralization through calcium and phosphorus deposition and 
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production of mineralization regulators (Jensen et al, 2010). These bone-forming cells have well 
developed Golgi complex, numerous mitochondria, and prominent rough Endoplasmic 
Reticulum (RER), reflecting their high metabolic activity and secretion (Pignolo et al, 2010).  
Osteocytes are terminally differentiated osteoblasts which are trapped in small cavities called 
lacunae within the bone matrix (Brandi, 2009). These resting cells exist in numbers 10 times 
higher than that of osteoblasts with the longest lifespan among all bone cells in the adult skeleton 
(Qing et al, 2009). Morphologically, osteocytes have smaller cell volume, RER and Golgi 
complex than osteoblasts depending on age and physical activity. Osteocytes have cell processes 
which form gap junctions with adjacent osteocytes and osteoblasts on the bone surface through 
networks of canaliculi. Osteocytes serve as mechanosensors which could detect physical changes 
in their environment. These properties help them to become involved in intercellular 
communication as well as bone formation, maintenance of bone integrity specifically the 
extracellular matrix, and recruitment of osteoblasts and osteoclasts during bone modeling and 
remodeling (Brandi, 2009; Qing et al, 2009). Additionally, Osteocytes play an active role in 
homeostatic regulation of calcium levels through immediate release of bone calcium into the 
blood during hypocalcemia (Qing et al, 2009). A recent study by Feng, et al suggests that 
osteocytes can also participate in bone remodeling and mineralization through phosphate 
regulation (Feng et al, 2009). 
Osteoclasts, the bone-resorbing cells, are derived from hematopoietic stem cells in bone marrow. 
Osteoclasts are motile, giant multi-nucleated cells, located on bone surfaces and in tight 
conjunction with the extracellular matrix (Vaananen et al, 1995). It has been shown that 
osteoblasts have an important regulatory effect in formation of osteoclasts from the fusion of 
their mononuclear osteoclast precursors (OCPs) (Boyce et al, 2009). Osteoclasts break down and 
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absorb both the collagen matrix and the deposited mineral of bones by secreting acid and 
hydrolytic enzymes (Brandi, 2009). Recent studies have identified other functions for osteoclasts 
in and around bone including regulation of differentiation of lining cells into osteoblasts, 
transition of hematopoietic cells from the bone marrow into the blood, and participation in 
immune responses through secretion of cytokines in inflammatory processes affecting bone 
(Boyce et al, 2009). 
 
Bone Modeling and Remodeling: 
The process through which the ability of bone to adapt its mechanical features including shape 
and size in response to mechanical loads is generated is referred to as “bone modeling” (Frost, 
1990-a). The process involving removal of a bone part followed by the formation of new bone is 
called “bone remodeling” (Frost, 1990-b).  
The modeling process occurs throughout the whole life cycle, from growth to adulthood (Brandi, 
2009). Any mechanical load could induce bone mechanical adaptation of its shape and size 
through continuous bone resorption and bone formation. Since these two processes are not 
balanced and often occur at different locations, the microstructure of the bone can change. Due 
to the independent action of osteoblasts and osteoclasts, bone modeling occurs less frequently 
than the remodeling process (Brandi, 2009; Frost, 1990-a). 
The remodeling process is a continuous phenomenon which occurs constantly throughout life. 
Bone remodeling is carried out at the level of the Basic Multicellular Unit, or BMU, which is 
composed of osteoclast and osteoblast cells collaborating closely on the surface of the bone 
(Weinstein et al, 2000). There are four distinct stages: quiescence/activation, resorption, reversal, 
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and formation. Bone remodeling process is initiated at a quiescent bone surface by contraction of 
the lining cells and recruitment of osteoclast precursors which, in turn, fuse to form active multi-
nuclear osteoclasts on the surface of the bone. Osteoclasts completely seal off the bone-
osteoclast interface area by adhering to the adjacent bone tissue matrix and create an isolated 
microenvironment (Roodman, 1999).  
During the resorption stage, the osteoclasts acidify and dissolve the mineral compartment of 
bone matrix by releasing hydrogen ions through membraneous proton pumps into the resorbing 
compartment. Additionally, secretion of lysosomal proteolytic enzymes helps with digestion of 
the organic component of the bone matrix. The result is the formation of saucer-shaped 
resorption cavities on the surface of the bone called Howship’s lacunae. At the end of this stage, 
osteoclasts undergo apoptosis (Reddy, 2004). 
Reversal phase, which is the transition state between bone resorption and bone formation, is 
characterized by transition of mononuclear pre-osteoblast cells into the resorption lacunae 
followed by their differentiation into osteoblasts (Ott, 1998; Brandi, 2009). 
The last phase of bone remodeling is a two-step process: ossification and calcification, both of 
which are carried out by osteoblasts. Ossification consists of formation and organization of bone 
extracellular matrix through synthesis of collagen and noncollagenous proteins that form the 
unmineralized organic matrix referred to as osteoid. Calcification includes subsequent 
mineralization of the matrix through which osteoblasts regulate calcium and phosphorus 
deposition (Brandi, 2009; Jensen et al, 2010). During the process, some osteoblasts become 
encapsulated within the osteoid and differentiate into osteocytes, while others continue to 
synthesize bone until they convert into quiescient lining cells that completely cover the new bone 
surface (Brandi, 2009).  
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The final product of bone remodeling is a new bone structural unit referred to as osteon. Each 
remodeling cycle takes about 6 months, most of which includes the formation stage (Brandi, 
2009). The frequency of bone remodeling depends on the type of the bone tissue. In cortical bone 
the BMU forms a cylindrical tunnel, whereas in trabecular bone the BMU is mainly on the bone 
surface. Due to the much larger surface area of trabecular bones, remodeling is processed more 
actively than compact bones (Ott, 1998). It has been estimated that in average about 25% of the 
trabecular bone and 3% of the compact bone undergo remodeling each year (Ott, 1998).  
Unlike bone modeling, the processes of bone resorption and formation are tightly coupled during 
bone remodeling. The “coupling” mechanism includes appearance and adherence of osteoblasts 
only to areas where osteoclasts have already been. In a homeostatic equilibrium, the balanced 
coupling mechanism can ensure continuous replacement of old bone with new tissue as well as 
maintenance of bone mechanical integrity and microstructure. However, if bone resorption rate 
exceeds the formation rate, the process is no longer coupled and a net loss of bone tissue occurs, 
which, in turn, could result in the development of osteoporosis in the long run (Ott, 1998; Brandi, 
2009). 
 
Osteoporosis: 
Osteoporosis is a chronic skeletal disease characterized by reduced bone mass associated with 
microarchitectural deterioration of bone tissue and compromised bone strength resulting in a 
consequent increase in bone fragility and susceptibility to fracture (Prentice, 2004; NIH, 2001). 
Osteoporosis is a major public health disease which according to the National Osteoporosis 
Foundation, affects 55% of Americans aged 50 and older. Currently in the US, 10 million people 
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are diagnosed with osteoporosis, 80% of which are women, and almost 34 million more have 
low bone mass, placing them at an increased risk for osteoporosis and bone fracture (National 
Osteoporosis Foundation, 2010-a). Of women aged 50 and older, 20% of non-Hispanic 
Caucasians and Asians, 5% of non-Hispanic African-Americans, and 10% of Hispanic women 
are affected by osteoporosis. The rate of low bone mass in these ethnic/racial groups is 52%, 
35%, and 49%, respectively. On the other hand, 7% of non-Hispanic white and Asian men, 3% 
of non-Hispanic African-American men, and 4% of Hispanic men are currently diagnosed with 
osteoporosis. The prevalence of low bone mass density among these ethnic/racial groups is 35%, 
19% and 23%, respectively. It is estimated that the risk of osteoporosis has the highest increasing 
rate among Hispanic women than all other ethnic/racial groups (National Osteoporosis 
Foundation, 2010-a).  
One of the major complications of osteoporosis is bone fracture. According to National 
Osteoporosis Foundation, one in two women and one in four men aged 50 and over will have an 
osteoporosis-related fracture in their lifetime (National Osteoporosis Foundation, 2010-a). The 
most common sites of fragility fractures are the wrist, spinal vertebrae and hip, although these 
fractures can occur anywhere in the body (Prentice, 2004). It has been shown that a main cause 
of morbidity and disability in the elderly is osteoporotic fractures, of which the hip fracture has 
the highest impact on quality of life. Hip fracture, mostly resulting from simple falls is associated 
with increased premature mortality (Chrischilles et al, 1994). As reported by Schurch et al, up to 
20% of patients who suffer from hip fracture die within six and twelve months of the event 
(Schurch et al, 1996). In another study by Sernbo et al, it was found that more than half of the 
hip fracture patients who survive the event would need long-term care (Sernbo et al, 1993). In 
addition, Osteoporotic fractures are a major burden to the global costs of healthcare, costing 
10 
 
many billions of dollars each year (Johnell, 1997). In 2005, a cost of $19 billion was spent for 
osteoporosis-related fractures. Experts predict that by 2025 these costs will increase to 
approximately $25.3 billion (National Osteoporosis Foundation, 2010-a). 
Osteoporosis can be classified as primary and secondary. Primary osteoporosis is the most 
common form of osteoporosis which is not associated with any other chronic disorders. This type 
of osteoporosis is mainly a disease of the elderly as a result of cumulative bone mass loss and 
impaired bone microstructure (Seeman, 2003; US Department of Health and Human Services, 
2004). Bone loss resulting from specific chronic diseases or use of certain medications is referred 
to as secondary osteoporosis (Soen, 2007). A wide variety of diseases can contribute to the 
development of secondary osteoporosis including endocrine or metabolic diseases such as 
hyperparathyroidism, diabetes mellitus, and Cushing’s syndrome; genetic disorders including 
cystic fibrosis and glycogen storage diseases; gastrointestinal diseases such as inflammatory 
bowel disease and celiac; hematologic disorders including hemophilia, thalassemia and sickle 
cell disease; malignancies such as leukemia; and many other chronic disorders (Harper et al, 
1998; Stein et al, 2003). Some of the most important medications associated with secondary 
osteoporosis include: glucocorticoids, anticonvulsants, anticoagulants, chemotherapeutic drugs, 
and thyroxin. Long-term glucocorticoid therapy is by far the most common cause of secondary 
osteoporosis (Soen, 2007; Stein et al, 2003). Secondary osteoporosis may occur at any age and 
affects both genders equally (US Department of Health and Human Services, 2004). 
Primary osteoporosis could be classified into Type I and Type II osteoporosis. The most 
common form of primary osteoporosis which occurs mainly in women within 15-20 years after 
menopause is referred to as primary type I or postmenopausal osteoporosis. The main 
complication of this type of osteoporosis is fractures of trabecular bones, of which distal radius 
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fractures (Colles fracture) caused by falls or minor accidents and lumbar vertebrae “crush” 
fractures due to compressional forces on the spine are the most common (Khosla et al, 1995). 
Also referred to as high turnover osteoporosis, postmenopausal osteoporosis is characterized by 
increased bone resorption and osteoclastic activity as a result of increased resorptive surfaces and 
higher numbers of osteoclasts (Boskey, et al, 2005). This is generally caused by the sudden 
estrogen deficiency and rapid bone calcium depletion in postmenopausal women resulting in 
bone mass loss of 2-5% per year after menopause (US Department of Health and Human 
Services, 2004; Arnaud et al, 1990).  
Primary type II osteoporosis or senile osteoporosis occurs after age 75 in both females and males 
and is frequently associated with fractures of hip and vertebrae (Khosla et al, 1995). Also 
referred to as age-related osteoporosis, type II osteoporosis results from normal aging and is 
associated with bone mass loss of 1-2% per year starting at age 35-40 years (US Department of 
Health and Human Services, 2004). This low turnover type of osteoporosis is characterized by 
reduced bone formation which is a result of decreased osteoblastic activity, and lower than 
normal numbers of osteoclasts and resorptive surfaces (Boskey, et al, 2005).  
Another form of primary osteoporosis is primary idiopathic osteoporosis which occurs in 
younger individuals including children, adolescents and young adults of both genders. In many 
cases of this rare form of disease, the exact cause of the disorder is unknown (Kulkarni et al, 
2004). 
Osteopenia, a precursor to osteoporosis is a much more common condition with an incidence rate 
of about three times higher than that of osteoporosis. Osteopenia is defined as low bone density, 
but not low enough to be osteoporosis, and will not necessarily develop into osteoporosis 
(Wehren, 2003). 
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Bone Strength and Bone Quality: 
Since osteoporosis is the systemic disease of compromised bone strength, great interest has 
recently developed in the factors that affect bone strength. Bone strength is defined as the ability 
of the bone to resist an applied force. Bone Mineral Density (BMD) accounts for approximately 
70-75% of the bone strength variance (Njeh et al, 1997), whereas the remaining variance is 
associated with bone quality which consists of a number of important factors including the bone 
turnover (rate of remodeling), mineralization, microarchitecture, and bone size and geometry 
(Seeman et al, 2006). The underlying concept of bone quality is that although the predicted 
fracture risk is similar among all osteoporotic patients, not all actually suffer from osteoporotic 
fractures (Ellison, 2005). A fracture is defined as a break in the continuity of bone when the 
external force applied to the bone exceeds its strength. The ability of the bone to resist a fracture 
depends on the amount of bone mass and size, bone macro- and microstructure, rate of bone 
remodeling, and other intrinsic properties of bone (Bouxsein, 2008). 
 
Bone Mineral Density and Bone Densitometry: 
Bone Mineral Density (BMD) measurement has four major applications in clinical practice: 
screening for osteoporosis, diagnosis of osteoporosis, prediction of fracture risk, and assessment 
of treatment efficacy and response to therapy (Baran et al, 1997). Bone mineral density or bone 
mineral content (BMC) refers to the bone mass per unit volume of bone. According to the World 
Health Organization (WHO), BMD is the only accepted quantitative measurement for accurately 
diagnosing osteoporosis and predicting fracture risk (World Health Organization, 1994). The 
WHO has defined the diagnostic criteria for osteoporosis based on the number of standard 
deviations that the BMC or BMD measured by bone densitometry techniques differs from the 
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young adult reference mean value for the population, referred to as a T-score. According to the 
WHO guidelines, the classification of Bone Mineral Density based on a T-score is as follows 
(World Health Organization, 1994): 
1. Normal – BMD (or BMC) not more than 1 standard deviation below the young adult 
reference mean value (T-score ≥ -1) 
2. Osteopenia - BMD (or BMC) between 1 and 2.5 standard deviations below the young 
adult reference mean value (-2.5 < T-score < -1) 
3. Osteoporosis - BMD (or BMC) more than 2.5 standard deviations below the young adult 
reference mean value ( T-score ≤ -2.5) 
4. Severe (established) Osteoporosis - BMD (or BMC) more than 2.5 standard deviations 
below the young adult reference mean value ( T-score ≤ -2.5) and the presence of one or 
more fragility fractures. 
A Z-score can also be calculated from an absolute BMD value. Z-scores are not as appropriate as 
T-scores for diagnostic purposes in clinical practice because they use age-adjusted controls as 
their reference. As a result, Z-scores become smaller in value as the age increases (Lenchik et al, 
2004). According to recommendations by the International Society for Clinical Densitometry 
(ISCD), for evaluating patients under 50 years of age including pediatric patients, Z-scores of 
equal to or less than -2.0 are associated with “low bone mineral content or bone mineral density 
for chronologic age” (ISCD, 2007). 
There are several bone densitometry techniques available for bone mineral density measurement. 
Traditional methods including conventional radiographs, single- and dual-photon absorptiometry 
(SPA and DPA), and single-energy X-ray absorptiometry (SXA) are no longer in use in clinical 
settings. Plain conventional radiographs applied on the hand bone do not have enough sensitivity 
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for osteoporosis diagnosis in bone mass losses of lower than 50% (South-Paul, 2001). SPA, DPA 
and SXA methods are restricted to areas with the lowest amount of surrounding soft tissue and 
therefore, are only applicable to the radius and calcaneus. All three techniques provide poor 
resolution and low precision with an error range of 3% to 5% (Ott, 1998). The only advantage of 
SXA over the other two methods is lower operating costs due to less radiation exposure (South-
Paul, 2001). 
The development of new noninvasive techniques through molecular and cellular research has 
provided the opportunity to better estimate the bone strength and fracture risk by quantitative 
assessment of bone macro- and microstructure. Quantitative computed tomography (QCT) 
measurements obtained through a specialized computerized tomography (CT) scanner can be 
used to measure the mineral content of the bone as a true volumetric density mainly on the 
lumbar spine (Ott, 1998). QCT has a precision error of 5% to 15% which is affected by the 
marrow fat in the vertebrae. Due to the inverse relationship between marrow fat and age, QCT 
has the potential of underestimation of bone density in older populations (Baran et al, 1997). 
However, QCT is the most sensitive method among all bone densitometry techniques (South-
Paul, 2001). This is due to the fact that QCT measurements are obtained only from trabecular 
bones which due to their higher surface area show the signs of bone loss much more rapidly than 
compact bones. This would allow for differentiated analysis of trabecular and cortical bones 
through the use of QCT method (Brandi, 2009). 
Peripheral quantitative ultrasound (QUS), mainly of the calcaneus, is the most widely used 
screening tool for osteoporosis in primary care and field studies. The advantages include lower 
cost, ease of application, possibility of using a portable device, and lack of radiation exposure 
(American College of Radiology, 2010). QUS measures two variables: speed of sound (SOS) 
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and broadband ultrasound attenuation (BUA). The two variables are then combined to obtain a 
third variable called quantitative ultrasound index or stiffness index (QUI). Speed of sound refers 
to the ratio of the bone width to the transit time of ultrasound signals. Attenuation is the loss of 
energy during the transit of sound waves through the bone (Njeh et al, 1997). All three variables 
are parameters of a different quality of bone strength than BMD that could provide additional 
information on fracture risk, all of which are more likely to have higher values in 
younger/healthier individuals than older/osteoporotic subjects (American College of Radiology, 
2010). The best approach with this technique is to identify individuals at higher risk for fractures 
and low BMD and to refer them for dual energy X-ray absorptiometry (DXA) for confirmation 
and diagnosis (American College of Radiology, 2010). 
Dual energy X-ray absorptiometry (DXA) is the gold standard for bone densitometry and 
osteoporosis diagnosis in clinical practice specifically on the hip and spine, the two major sites of 
bone fractures (American College of Radiology, 2010). DXA scans can also be used to measure 
the bone density of the wrist, heel and total body (Ott, 1998). DXA measurements of the bone 
mineral content are expressed as a surface density rather than the true volumetric density 
measured by QCT, and allow for separate analysis of bone and soft tissue unlike SPA, DPA and 
SXA methods (Ott, 1998). DXA has the highest precision among all bone densitometry 
techniques with a precision error rate of 0.5% to 1% (Ott, 1998; South-Paul, 2001). Other 
advantages of this technique include: short scan times, low radiation exposure and lower 
operating costs (Ott, 1998; South-Paul, 2001). 
Due to the low correlation among bone densitometry techniques, the use of different devices as 
well as the choice of the site of measurement could result in inconclusive diagnoses (Varney et 
al, 1999). A study by Faulkner et al reported the following osteoporosis diagnosis rates in 
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women over 60 years: 50% with QCT of the spine, 6% with DXA of the total hip, 14% with 
DXA of the lumbar spine, and 3% with the heel QUS (Faulkner et al, 1999). 
As any other diagnostic tool, BMD has its own limitations for use. BMD has a recognized 
inverse and exponential relationship with future fracture risk, but there is no defined value of 
bone mineral density for which the fracture risk could be considered zero (Marshall et al, 1996). 
Additionally, individuals with normal or osteopenic T-score values could still suffer from 
osteoporotic fractures. A study in 2004 by Siris et al reported a high occurrence of bone fracture 
of about 82% with T-score values of above -2.5 calculated by peripheral bone densitometry 
(Siris et al, 2004). In another study in 2004, Schuit et al reported that relatively high incidences 
of bone fractures of about 56% and 79% in females and males, respectively, were associated 
with T-score values of greater than -2.5 measured for hip BMD by DXA (Schuit et al, 2004).  
Although used as the basis of osteoporosis diagnosis by the WHO, bone mineral density is not 
useful in comparing different ethnic/racial populations. Studies on bone mineral density and 
fracture risks in different ethnic/racial populations suggest that East Asians who are genetically 
shorter and of smaller body sizes, tend to have lower bone mineral density compared to Western 
populations with taller statures. However, the osteoporotic fracture rates do not differ among the 
two populations (Aspray et al, 1996; Prentice et al, 1994; Russel-Aulet et al, 1993; Yan et al, 
1997). 
Despite all the above-mentioned limitations, bone densitometry is the only technology available 
for accurate measurement of bone mass density and prediction of bone fracture risk, to the extent 
that its efficacy in prediction has been shown to be as equal or even higher than that of blood 
cholesterol measurement for prediction of cardiovascular diseases and blood pressure testing for 
stroke (American College of Radiology, 2010). It is recommended that osteoporosis should be 
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diagnosed on the basis of BMD even before the occurrence of fractures. The use of the WHO 
criteria for diagnosis of osteoporosis should only be made based on DXA scans of the hip and 
spine (American College of Radiology, 2010). 
 
Bone Turnover: 
Bone remodeling can be assessed by the measurement of biochemical markers of bone turnover 
in the blood or urine.  These markers consist of bone tissue enzymes released from bone cells 
and non-enzymatic peptides derived from collagen and non-collagenous proteins during bone 
turnover (Seibel, 2005). Markers of bone formation include serum levels of total alkaline 
phosphatase, bone-specific alkaline phosphatase, osteocalcin, and procollagen type I C-terminal 
(PICP) and N-terminal (PINP) extension peptides.  Markers of bone resorption include urinary 
levels of pyridinoline and deoxypyridinoline, serum levels of tartrate-resistant acid phosphatase 
and bone sialoprotein, and serum and urinary levels of C-terminal and N-terminal cross-linking 
type I collagen telopeptides (Seibel, 2005). Prior to detection of any bone mineral density 
changes, the level of these bone turnover markers reflect changes in bone remodeling within a 
short period of time, ideally only the osteoblastic and osteoclastic activity. 
According to the NIH consensus conference, “these biochemical markers of bone turnover do not 
predict bone mass or fracture risk and are only weakly associated with changes in bone mass. 
Therefore, they are of limited utility in the clinical evaluation of individual patients.” (NIH, 
2000) 
Based on the National Osteoporosis Foundation guidelines, although biochemical markers of 
bone turnover are useful in assessment of bone loss, risk of fracture, and efficacy of treatment, 
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these tests cannot be used in place of BMD testing for diagnosis of osteoporosis since they are 
not yet standardized (National Osteoporosis Foundation, 2010-b). 
A 3-year study by Borah et al showed that high rates of bone turnover in postmenopausal women 
was associated with loss of bone mass, impaired trabecular bone microstructure and decreased 
bone mineralization, all of which were related to increased osteoclastic and reduced osteoblastic 
activity (Borah et al, 2004). In several studies on bone turnover markers, these remodeling rate 
indices were shown to predict fracture risk. A large cohort study by Garnero et al reported that 
increased bone turnover markers were predictors of hip fracture risk independent of BMD 
(Garnero et al, 1996). 
 
Osteoclast Differentiation and Bone Remodeling: 
Normal bone remodeling is a coupled event between bone resorption and formation. This 
mechanism requires occurrence of osteoblast-mediated bone formation in the exact areas of bone 
resorption through osteoclastic activity. These areas normally include structurally weak bone due 
to either bone disuse or mechanical stress. Under these circumstances, osteocytes serve as 
mechanosensors to detect physical changes in the networks of canaliculi. Upon detection of 
change in the flow of bone fluid, osteocytes send signals to osteoblasts, which in turn, stimulate 
osteoclast differentiation and activation, resulting in bone resorption (Sims et al, 2008; 
Teitelbaum, 2000). 
Differentiation of osteoclast precursors into mature osteoclasts is mediated through two 
cytokines secreted by osteoblasts; macrophage colony stimulating factor (MCSF) (Teitelbaum, 
2000; Matsuo et al, 2008), and receptor activator of nuclear factor-κB (RANK) ligand (RANKL) 
(Seeman, 2009). RANKL, a tumor necrosis factor (TNF)-related activation-induced cytokine 
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(TRANCE) (Yaturu, 2009), is the key regulator of osteoclastogenesis through binding to its 
receptor (RANK) on the plasma membrane of osteoclast progenitors and stimulating their 
differentiation (Seeman, 2009; Yaturu, 2009). Osteoprotegerin (OPG), a decoy receptor for 
RANKL, is also secreted by osteoblasts to inhibit RANK-RANKL interaction and osteoclast 
differentiation (Asagiri et al, 2007). Some systemic hormones that enhance osteoclastic activity 
through either upregulation of RANKL and MCSF or inhibition of OPG expression include: 
parathyroid hormone (PTH), 1,25-dihydroxy vitamin D, thyroid hormones, and prolactin 
(Teitelbaum, 2000; Miura et al, 2002; Seriwatanachai et al, 2008; Zaidi, 2007). Other stimulants 
of osteoclastogenesis include TNF-α, prostaglandin E2, and transforming growth factor (TGF)-β 
superfamily (Fuller et al, 2002; Li et al, 2000), specifically bone morphogenetic proteins (BMPs) 
which are members of the (TGF)-β family and are released from bone during bone resorption 
(Itoh et al, 2001). 
The remodeling process is a continuous phenomenon which occurs constantly throughout life. 
Bone remodeling is carried out at the level of the Basic Multicellular Unit, or BMU, which is 
composed of osteoclast and osteoblast cells collaborating closely on the surface of the bone 
(Weinstein et al, 2000). There are four distinct stages: quiescence/activation, resorption, reversal, 
and formation. Bone remodeling process is initiated at a quiescent bone surface by contraction of 
the lining cells and recruitment of osteoclast precursors which, in turn, fuse to form active multi-
nuclear osteoclasts on the surface of the bone. Osteoclasts completely seal off the bone-
osteoclast interface area by adhering to the adjacent bone tissue matrix and create an isolated 
microenvironment, termed a resorption lacuna (Roodman, 1999).  
During the resorption stage, the osteoclasts acidify the resorption lacuna and dissolve the mineral 
compartment of the bone matrix by releasing hydrogen ions through membraneous proton pumps 
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into the resorbing compartment. During this phase, hydrogen ions in the form of proton are 
generated through the action of carbonic anhydrase II on carbon dioxide and water within the 
osteoclasts. The active transport of protons across the membrane is coupled with the passive 
transport of chloride through chloride channels, forming hydrochloric acid for dissolution of the 
inorganic compartment of bone matrix (Reddy, 2004; Supanchart et al, 2008). Additionally, 
secretion of lysosomal proteases and cathepsin K enzyme from osteoclasts helps with digestion 
of the organic component of the bone matrix, specifically type I collagen fibrils (Teitelbaum, 
2000; Supanchart et al, 2008). The result is the formation of saucer-shaped resorption cavities on 
the surface of the bone called Howship’s lacunae. At the end of this stage, osteoclasts undergo 
apoptosis (Reddy, 2004). 
Reversal phase, which is the transition state between bone resorption and bone formation, is 
characterized by transition of mononuclear pre-osteoblast cells into the resorption lacunae 
followed by their differentiation into osteoblasts (Brandi, 2009). 
The last phase of bone remodeling is a two-step process: ossification and calcification, both of 
which are carried out by osteoblasts. Ossification consists of formation and organization of bone 
extracellular matrix through synthesis of type I collagen fibrils and noncollagenous proteins that 
form the unmineralized organic matrix referred to as osteoid. Calcification includes subsequent 
mineralization of the matrix through which osteoblasts regulate calcium and phosphorus 
deposition in the presence of alkaline phosphatase and two of the newly identified bone 
polypeptides: osteocalcin and osteopontin (Brandi, 2009; Jensen et al, 2010). Finally, mature 
hydroxyapatite crystals [Ca10(PO4)6(OH)2] are formed by gradual addition of hydroxide ions to 
calcium and phosphorus (Sims et al, 2008). During the process, some osteoblasts become 
encapsulated within the osteoid and differentiate into osteocytes, while others continue to 
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synthesize bone until they convert into quiescient lining cells that completely cover the new bone 
surface (Brandi, 2009). Upregulators of osteoblasts and bone formation include insulin-like 
growth factor (IGF)-1, insulin, and OPG (Zaidi, 2007; Seeman, 2009). The family members of 
(TGF)-β including BMPs seem to stimulate both resorption and formation (Seeman, 2009).  
 
New Links Between Bone, Adipose Tissue and Glucose Metabolism: 
In the last decade, emerging evidence suggests important and active metabolic roles for both 
skeletal and adipose tissue. Although adipose tissue was initially regarded as an inert and 
exclusive site of storage for fat and energy, recent findings have revealed that adipose tissue has 
both paracrine and endocrine roles by producing peptides and cytokines which can modulate 
metabolic homeostasis, both locally and systemically (Scherer, 2006). Similarly, skeleton has 
long been considered as a passive tissue only capable of bone remodeling and regulation of 
calcium homeostasis within its own structural context. However, recent evidence supports the 
hypothesis that bone is an endocrine organ and a regulator of global energy metabolism through 
control of glucose homeostasis (Fukumoto et al, 2009).  
Recent findings suggest that complex relationships exist between adipose tissue and skeleton to 
integrate bone remodeling and glucose and energy metabolism. These interactions are well 
identified in rodents, but are less clear in humans. Osteoblasts and adipocytes are both present in 
the bone marrow and share a common mesenchymal stem cell (MSC) origin (Yaturu, 2009). 
The first evidence came with a landmark study by Ducy et al in 2000 where they found that 
leptin, an adipocyte-secreted hormone with an already well established role as a regulator of 
energy balance and body weight and a stimulant of thermogenesis via hypothalamic receptors 
(Jéquier, 2002), can indirectly affect bone remodeling through enhanced activity of sympathetic 
22 
 
nervous system (Ducy et al, 2000). Increased sympathetic output by leptin activates the β2-
adrenergic receptors in osteoblasts and subsequently decreases bone formation, while increasing 
bone resorption through enhanced expression of RANKL, the osteoclast differentiation factor in 
osteoblast cells (Ducy et al, 2000). The influence of leptin on bone remodeling has been shown 
to be independent of its role in energy balance regulation (Shi et al, 2008).  
Leptin can also affect bone through mechanisms independent of the neural pathway. One 
mechanism is improvement of insulin sensitivity by possibly inducing insulin-like growth factor-
binding protein 2 (IGFBP2), causing positive effects on the bone (Hedbacker et al, 2010). 
Another possible effect of leptin on bone is through its receptors on osteoblasts which help in 
direct action of leptin on stimulation of osteoblast formation and proliferation as well as 
inhibition of osteoclast differentiation. This could result in opposite effects than those observed 
with leptin acting via central nervous system (Cornish et al, 2002; Holloway et al, 2002). 
Another important emerging evidence of the active regulatory effect of bone in energy 
metabolism is the newly identified role of osteoblasts and their specific molecules and genes in 
glucose homeostasis control. Osteocalcin, a bone-specific protein product is secreted by 
osteoblasts into the bone extracellular matrix and has a regulatory role in systemic energy 
metabolism. Osteocalcin undergoes post-translational vitamin K-dependent gamma-
carboxylation of three of its glutamic residues which helps the molecule to acquire higher 
affinity for hydroxyapatite and to incorporate calcium ions into these crystals in the 
mineralization process of the bone extracellular matrix (Clemens et al, 2011). On the contrary, 
the under- or undecarboxylated form of osteocalcin has a low affinity for hydroxyapatite and is 
more likely to be released into the systemic circulation for its endocrine functions. It has been 
shown that the undercarboxylated osteocalcin acts as a hormone on both the pancreatic β-cell and 
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adipocyte proliferation and gene expression and subsequently stimulates insulin production, 
improves insulin sensitivity, enhances adiponectin secretion and decreases lipid accumulation. 
The simultaneous increase in insulin sensitivity and decrease in fat mass could result in the 
enhancement of energy expenditure in the body (Lee et al, 2007; Ferron et al, 2008). A recent 
study by Vestri et al has reported an increase in both basal and insulin-stimulated glucose 
transport as a result of the undercarboxylated osteocalcin activity (Vestri et al, 2008). 
Adiponectin, an adipocyte-secreted adipokine in both subcutaneous and visceral adipose tissue is 
produced in response to osteoblastic osteocalcin secretion. Adiponectin has been shown to 
increase both hepatic and adipocytic insulin sensitivity (Kershaw et al, 2004; Kadowaki et al, 
2005) and its low levels have been associated with insulin resistance in diabetic patients (Magni 
et al, 2010). This insulin-sensitizing factor could also have a negative impact on bone mineral 
density and seems to be an independent predictor of low bone mass (Magni et al, 2010).  
A recent study by Lee et al in rodents showed that osteoblasts express the Esp gene which 
encodes an intracellular receptor-like protein tyrosine phosphatase, termed osteotesticular protein 
tyrosine phosphatase (OST-PTP). It was also found that Esp-deficient mice (ESP-/-) showed 
characteristics of hyperinsulinemia due to increased pancreatic β-cell proliferation, increased 
insulin secretion and improved insulin sensitivity, as well as increased adiponectin production 
and decreased visceral fat tissue. On the contrary, overexpression of Esp gene resulted in a 
metabolic phenotype similar to type 2 diabetes with increased insulin resistance and impaired 
glucose tolerance. Therefore, OST-PTP was found to be a preventative factor in glucose 
homeostasis by inhibiting endocrine functions of osteocalcin (Lee et al, 2008). Additionally, the 
exact metabolic phenotype of Esp-deficient mice has been observed in more recent studies with 
24 
 
overexpression of undercarboxylated osteocalcin gene, where hypoglycemia, hyperinsulinemia 
and increased insulin sensitivity were the typical characteristics (Lee et al, 2008).   
In summary, the inactivation of Esp gene in osteoblasts results in an increase in the release of 
undercarboxylated osteocalcin and subsequently improves insulin sensitivity and glucose 
metabolism as well as decreasing adiposity. As a result, energy metabolism is positively 
regulated through increased energy expenditure due to enhanced glucose and lipid metabolism 
(Kim et al, 2010).  
 
Osteocalcin and Glucose/Fat Metabolism in Humans: 
It should be noted that Esp gene is a pseudogene in humans and a human homolog has not yet 
been identified. However, protein-tyrosine phosphatase 1B (PTP-1B) expressed in human 
osteoblasts is a close functional homolog of Esp and could possibly have the same functions 
(Cousin et al, 2004). Several recent studies have shown associations between serum total 
osteocalcin with parameters of glucose metabolism and insulin sensitivity as well as visceral fat 
mass in humans. Fernandez-Real et al found a strong positive impact of circulating osteocalcin 
concentrations on improved insulin sensitivity and lowered fasting plasma glucose and showed 
an increase in serum osteocalcin as a result of weight loss, supporting the hypothesis of an 
inverse relationship between circulating osteocalcin and fat mass in humans (Fernandez-Real et 
al, 2009). The same associations between osteocalcin and glucose and fat metabolism have been 
found in studies by Kindblom et al in older Swedish men (Kindblom et al, 2009), Yeap et al in 
older Australian men (Yeap et al, 2010), Saleem et al in African-Americans and non-Hispanics 
(Saleem et al, 2010), Im et al in postmenopausal Korean women (Im et al, 2008), Winhofer et al 
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in gestational diabetes patients (Winhofer et al, 2010), Pittas et al in elderly males and females 
(Pittas et al, 2009), and Zhou et al in Chinese population (Zhou et al, 2009).  
Researches on undercarboxylated osteocalcin in humans are much fewer and more inconsistent 
than those carried out on total osteocalcin. In two studies by Kanazawa et al it was found that 
undercarboxylated osteocalcin was inversely related with fasting plasma glucose and fat mass in 
men, but not in postmenopausal women (Kanazawa et al, 2009; Kanazawa et al, 2010). Unlike 
rodent models, increased carboxylated osteocalcin level, and not the undercarboxylated form, 
was shown to be associated with improved insulin sensitivity in humans (Yoshida et al, 2008). 
Additionally, in a recent study by Shea et al only elevated circulating total and carboxylated 
forms of osteocalcin were associated with lower insulin resistance, and undercarboxylated 
osteocalcin had no such effect, despite the strong evidence in mice (Shea et al, 2009).  
The inconsistent observations in human studies derive from the fact that the results are all based 
on measurements of serum levels of osteocalcin - unlike the use of recombinant uncarboxylated 
osteocalcin in therapeutic or pharmacologic doses in rodent genetic models- and that there are 
several limitations in the ability of accurately measuring these circulating levels in humans 
(Motyl et al, 2010). In addition, osteocalcin status in humans is heavily dependent on several 
factors including age, gender, physical activity, smoking, and nutritional status (Nimptsch et al, 
2007). On the other hand, since all the aforementioned human studies are cross-sectional, they 
can only prove relationships but cannot establish causality between osteocalcin and glucose 
metabolism, or confirm whether the association between serum osteocalcin and visceral fat mass 
in humans is dependent or independent of insulin action. As a result, more clinical studies are 
needed to investigate these issues and to determine whether uncarboxylated, carboxylated or 
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total osteocalcin is responsible for the regulation of glucose metabolism in humans (Motyl et al, 
2010). 
 
Insulin Regulation on Bone Function: 
The mechanism through which OST-PTP inhibits the release of undercarboxylated osteocalcin in 
osteoblasts and acts as a preventative factor in glucose homeostasis was unknown until recently. 
The finding was surprising by itself since this intracellular protein tyrosin phosphatase could not 
be directly involved in the carboxylation of an extracellular protein (Clemens et al, 2011). Based 
on the observed influence of osteocalcin on insulin, it was hypothesized that there is a reciprocal 
action of insulin on osteocalcin expression or activity.  
Insulin receptors are present in osteoblasts in large numbers. The insulin receptor is a receptor 
tyrosine kinase which can be upregulated by phosphorylation through exposure to physiological 
levels of insulin and downregulated by dephosphorylation through the action of protein tyrosine 
phosphatases (Schlessinger, 2000). Protein tyrosin phosphatase OST-PTP has been reported to 
regulate osteocalcin carboxylation through dephosphorylation of insulin receptor in osteoblasts 
(Clemens et al, 2011). It has been shown that the insulin receptor is a substrate of both OST-PTP 
and PTP-1B in osteoblasts of rodents and humans, respectively; that is, the insulin signaling is 
negatively regulated by these two protein tyrosin phosphatases (Delibegovic et al, 2009). The 
finding of the insulin receptor as a substrate for OST-PTP or PTP-1B could be of importance for 
two novel hypotheses: (1) insulin signaling in bone osteoblasts is required for whole-body 
glucose homeostasis, supporting the emerging evidence for the regulatory role of bone in global 
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energy metabolism, and (2) insulin signaling could regulate osteocalcin expression or activity 
(Clemens et al, 2011). 
A recent study by Ferron et al in 2010 showed that mice deficient in osteoblastic insulin receptor 
(InsRob-/-) have a glucose intolerance-like phenotype with hyperglycemia and hypoinsulinemia, 
along with decreased uncarboxylated osteocalcin levels (Ferron et al, 2010). Another experiment 
by the same group on double-mutant heterozygous mice lacking one allele of osteocalcin and one 
allele of the insulin receptor in osteoblast (Ocn+/- ; InsRob+/-) reported the same impaired glucose 
tolerance phenotype as observed in either the insulin receptor mutant mice (InsRob-/-) or 
osteocalcin-deficient mice (Ocn-/-) (Ferron et al, 2010).  
The results of Ferron et al study confirmed the hypothesis that insulin signaling in osteoblasts 
could regulate the activity of osteocalcin by promoting its decarboxylation. This mechanism of 
action of insulin signaling was further analyzed in a study by Fulzele et al. They studied the 
skeletal phenotype of mice deficient in insulin receptors in osteoblasts and found impaired bone 
acquisition and low bone density in their trabecular bones as a result of reduced osteoblastic 
proliferation and bone formation. Surprisingly, osteoclastic activity was also decreased in these 
mutant mice (Fulzele et al, 2010). These findings led the researchers to believe that insulin 
signaling not only impacts bone formation, but also regulates bone resorption.  
The positive impact of insulin signaling on bone formation is coupled to transcriptional control 
of osteoblast proliferation and differentiation through suppression of Runx2 inhibitors, Twist2 
and FoxO1 (Fulzele et al, 2010). Runx2 is an osteoblast transcription factor which stimulates 
differentiation of mesenchymal stem cells into osteoblasts (Komori, 2010; Confavreux, 2011). 
The transcription factor Twist2 is a downstream suppressor of osteoblast differentiation through 
Runx2 inhibition (Bialek et al, 2004). FoxO1, a member of the forkhead family of transcriptional 
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factors which promotes gluconeogenesis in hepatocytes, is a negative regulator of insulin 
receptors in osteoblasts, adipocytes, myocytes, hepatocytes, and pancreatic β-cells (Nakae et al, 
2002; Gross et al, 2008;). FoxO1 deficiency in osteoblasts has been shown to be associated with 
hyperinsulinemia and enhanced insulin sensitivity related to decreased Esp gene expression and 
increased osteocalcin secretion, suggesting the role of osteoblasts in FoxO1 regulation of glucose 
metabolism (Rached et al, 2010). 
The mechanism of action of insulin signaling on the upregulation of bone resorption by 
osteoclasts could be explained by the effect of insulin on suppression of osteoprotegrin (OPG) 
expression in osteoblasts (Ferron et al, 2010; Fulzele et al, 2010). As noted earlier, OPG is 
secreted by osteoblasts to block osteoclastogenesis by acting as the decoy receptor for RANKL 
and inhibiting RANK-RANKL interaction on the plasma membrane of osteoclast progenitors 
(Asagiri et al, 2007). Suppression of OPG expression by insulin signaling results in a decrease in 
the OPG/RANKL ratio and thus, causes an overexpression of Tcirg1 and cathepsin K in 
osteoclasts (Ferron et al, 2010; Fulzele et al, 2010). Cathepsin K is a lysosomal proteolytic 
enzyme which digests the organic component of the bone matrix, specifically type I collagen 
fibrils (Teitelbaum, 2000; Supanchart et al, 2008). Tcirg1, another osteoclast-specific gene, 
encodes a proton pump subunit required for acidification of the bone extracellular matrix in the 
resorption lacunae. This lowers the pH to an approximate acidity of 4.5, sufficient for 
decarboxylation and activation of osteocalcin (Ferron et al, 2010; Fulzele et al, 2010). Thus, it is 
the role of the osteoclasts to ultimately determine the form and function of osteocalcin produced 
by osteoblasts (Ferron et al, 2010). The undercarboxylated osteocalcin then acts as a circulating 
hormone to promote insulin secretion and sensitivity as well as adiponectin production, resulting 
in increased energy expenditure.  
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These results indicate the existence of a feed-forward bone-pancreas endocrine loop through 
which insulin signaling in the osteoblasts stimulates undercarboxylated osteocalcin secretion, 
which in turn promotes insulin secretion and sensitivity for regulation of glucose homeostasis 
and energy metabolism. This feed-forward mechanism adds further credence to the emerging 
evidence that insulin signaling in osteoblasts is required for the whole-body glucose metabolism 
and that bone is an important regulator of energy homeostasis (Ferron et al, 2010; Fulzele et al, 
2010; Confavreux, 2011).  
 
Diabetes-induced Osteoporosis: 
There is relatively strong evidence to suggest that type 1 diabetes has negative impacts on bone 
health, specifically bone mineral density. On the other hand, there seems to be more discrepancy 
in skeletal effects of type 2 diabetes. While many studies have shown normal to high BMD 
values in individuals with type 2 diabetes, some have found low BMD values.  
In a research study by Lumachi et al in 2009, a small group of adult men and women with type 1 
diabetes were recruited and matched with healthy controls by age, gender and BMI in order to 
study the association between osteopenia and bone health variables including bone mass density. 
The results of this study showed that the BMD value at the lumbar spine and femoral neck in 
type 1 diabetic patients was about 60% lower than the controls (Lumachi et al, 2009). A similar 
study by Saha et al in 2009 on adolescent men and women with type 1 diabetes reported low 
BMD values in cortical bones and proximal femur, as well as reduced bone size compared to 
healthy peers. This diminish in BMD values seemed to affect male adolescents more than 
females (Saha et al, 2009). 
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Unlike type 1 diabetes, the impact of type 2 diabetes on bone health has been shown to be 
conflicting. Some studies have reported protective effects, whereas some others have shown 
negative impact. Yamaguchi et al in a research study in 2009 found higher BMD values at the 
femoral neck in men with type 2 diabetes, however they reported a lower prevalence of vertebral 
fractures in the same population (Yamaguchi et al, 2009). However, Yaturu and colleagues found 
significantly lower BMD values, as well as increased incidences of osteoporosis at hip bone in 
veteran men with type 2 diabetes compared to age-matched controls (Yaturu et al, 2009).  
 
Possible Mechanisms of Diabetes-induced Impaired Bone Strength and Osteoporosis: 
Hyperglycemia is a typical clinical feature of both type 1 and type 2 diabetes. It is hypothesized 
that hyperglycemia is the major factor which is responsible for the detrimental effects of diabetes 
on bone metabolism and bone quality, both directly and indirectly. Hyperglycemia increases 
osteoclast function through mechanisms discussed earlier, including increase in number of 
osteoclasts, since glucose is the main energy source for osteoclasts (Williams et al, 1997), as well 
as induction of TNF-α, MCSF and RANKL production from osteoblasts to activate osteoclast 
proliferation and differentiation. Hyperglycemia could also impair osteoblast function through 
decreasing osteocalcin production and in turn, osteoblast proliferation. The end-result of these 
mechanisms would be accelerated bone resorption and suppressed bone formation, leading to 
osteopenia and osteoporosis (Wongdee et al, 2011). 
Hyperglycemia can also reduce the number of endeothelial progenitor cells, lining the blood 
vessels. This could result in decreased angiogenesis, which could in turn, retard bone formation 
and repair at fracture sites and further aggravate bone loss (Wongdee et al, 2011). Additionally, 
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high blood glucose can promote an adipocyte-like phenotype by overexpression of adipocyte 
differentiation markers including PPARγ. This adipogenic differentiation of mesenchymal cells 
causes an osteoblast-to-adipocyte shift, and thus suppresses osteoblast differentiation and bone 
formation (McCabe, 2007; Wongdee et al, 2011).   
A major mechanism of hyperglycemia in impairing mechanical characteristics and bone strength 
is by formation of Advanced Glycation Endproducts (AGEs) or non-enzymatic cross-links in 
type 1 collagen fibers. These permanent glucose-derived cross-links can contribute to decreased 
bone rigidity and bone quality and increases bone fragility in type 1 and type 2 diabetes (Saito et 
al, 2010). 
 
Specific Mechanisms of Type 1 Diabetes: 
It is clearly known now that type 1 diabetes primarily decreases bone formation, rather than 
increasing bone resorption, as its major skeletal effect. This would in turn, induce the osteoblast-
to-adipocyte shift and promote bone marrow adiposity (McCabe, 2007). Along with 
hyperglycemia, hypoinsulinemia is another major contributor to bone fragility in type 1 diabetes. 
Insulin is an anabolic hormone and its deficiency can negatively impact bone turnover, majorly 
by reducing osteoblast proliferation and function (McCabe, 2007). Additionally, 
hypoinsulinemia leads to a deficiency in insulin-like growth factor (IGF-1), which in turn, results 
in low BMD values in type 1 diabetes (Botolin et al, 2007). On the other hand, GH/IGF axis is a 
major mechanism contributing to decreased bone formation, since IGF-1R is required for 
anabolic effects of growth hormone (GH) in osteoblasts in vivo (DiGirolamo et al, 2007). 
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An indirect contributor to type 1 diabetes-induced osteoporosis is impaired adipokines secretion 
and function including leptin (Elefteriou, 2008). The mechanism is not yet clear, but it has been 
shown that leptin is an activator of bone resorption (Elefteriou et al, 2005; Shi et al, 2008). 
 
Specific Mechanisms of Type 2 Diabetes: 
Unlike type 1 diabetes that is characterized by low body weight, hypoinsulinemia, and low IGF-1 
levels which all adversely impact bone status, type 2 diabetes is characterized by overwight and 
obesity, and hyperinsulinemia at early stages, all of which could have potential anabolic effects 
on bone that can counteract the negative effects of hyperglycemia (Cutrim et al, 2007).  
However, advanced insulin resistance in later stages of type 2 diabetes along with increased 
levels of AGEs and diabetic complications could lead to detrimental effects on mechanical bone 
properties (Merlotti et al, 2010). On the other hand, although obesity can have a protective role 
on BMD by increasing the mechanical load on the bone, an increase in adiposity as well as 
insulin resistance during poor glycemic control could result in upregulation of cytokines, 
adipokines and leptin which in turn, promotes inflammation. Inflammation is a major risk factor 
for high bone turnover, bone fracture and osteoporosis (Wisse, 2004; Clowes et al, 2005; Ginaldi 
et al, 2005; Tilg et al, 2008). 
Limited research suggests a role of low vitamin D and calcium homeostasis in the development 
of type 2 diabetes, specifically during poor glycemic control.  A systematic review and meta-
analysis on the role of vitamin D and calcium in type 2 diabetes by Pittas and colleagues in 2007 
suggested an association between low vitamin D status, calcium intake, and risk of type 2 
diabetes in observational studies (Pittas et al, 2007). However, intervention studies have shown 
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small benefits of vitamin D supplementation alone, but positive effects of combined vitamin D 
and calcium in preventing type 2 diabetes among populations most at-risk (Hitz et al, 2007). On 
the other hand, diabetic nephropathy as a complication of type 2 diabetes has been shown to 
increase bone fragility and decrease bone quality through impaired secretion of Parathyroid 
Hormone (PTH), low bone turnover, and accumulation of microdamage in bone (Inaba et al, 
2005). 
Overall, obesity and over-glycosylation of collagen fibers are two important factors contributing 
to increased bone fracture risk in type 2 diabetes, independent of bone mass density (de Paula et 
al, 2010). 
The present study was conducted due to the conflicting results of the relationship between 
diabetes and bone mineral density, specifically in type 2 diabetes. This study is aimed at 
elucidating the effect of diabetes-related variables on bone health status and bone mineral 
density, especially in osteoporosis, in both adult men and women.  
34 
 
Objectives: 
In an effort to examine the bone mass density (BMD) of adult men and women with pre-, type 1 
and type 2 diabetes, we aimed to: 
1. compare BMD by diabetes status. 
2. determine frequency of low BMD (T-score < -1) by type of diabetes. 
3. determine if demographics, lifestyles and health behaviors, history of falling or bone 
fracture, current status or history of conditions and medication use, and female 
reproductive history explain any of the variance in BMD in this population. 
4. determine if family history of diabetes and any of the bone diseases contribute to the 
variance in BMD. 
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Hypotheses: 
1. BMD levels are significantly lower in individuals with type 1 diabetes and are 
significantly higher in individuals with type 2 diabetes. 
2. Frequency of low BMD (T-score < -1) is significantly higher in subjects with type 1 
diabetes than those with type 2 diabetes. 
3. Older age and being a female are significant contributors to the variance in BMD. 
4. Those with vigorous or moderate physical activity have significantly higher BMD values 
than those who do not have any exercise. 
5. BMD is significantly lower in individuals with a history of falling or bone fracture.  
6. Women who have undergone menopause have significantly lower BMD values than 
those who have not yet experienced it. 
7. Family history of diabetes and/or bone diseases contributes significantly to the variance 
in BMD. 
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CHAPTER 2 
METHODOLOGY 
 
Population: 
Individuals with type 1 or 2 diabetes were recruited to participate in this study. 
 
Subject Recruitment: 
Subject inclusion criteria were to have diabetes and be 18 years of age or older. Adults over age 
65 were not specifically included nor excluded.  
Various methods of recruitment were utilized. The first round of recruitment was through E-
week, the weekly University of Illinois faculty/staff electronic mail newsletter with brief 
summaries of campus announcements. The recruitment announcement was made twice during 
Fall 2009 and once during Spring 2010 semesters. The announcement invited those with diabetes 
to participate in the bone health screening study by having their bone mass density checked 
through a heel ultrasound screening test, filling out a short questionnaire, having their 
anthropometric measurements taken and contributing their saliva to determine the relationship 
between diabetes and osteoporosis in terms of genetic markers (See Appendix A for the 
recruitment announcement).  
The second round of recruitment consisted of posting flyers all around campus on public bulletin 
boards and placing advertisements in the Daily Illini (DI) newspaper. DI is the independent 
student newspaper of the University of Illinois. The flyers and advertisements contained the 
same information as the E-week announcements. Permission was sought from the Institutional 
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Review Board (IRB) at the University of Illinois at Urbana-Champaign prior to hanging up flyers 
and posting ads to the newspaper (See Appendix B for the recruitment flyer and Appendix C for 
DI ad). 
Since enough samples were not recruited through previous methods, we expanded the recruiting 
efforts to local diabetes support groups, including Senior High Rise Diabetes Mellitus Outreach 
Groups at Champaign-Urbana Public Health Department (CUPHD). The recruitment consisted 
of the student researcher attending one of the group’s monthly meetings and explaining about the 
research study. This was done at two of their sites: Washington Square in Urbana, and Round 
Barn in Champaign. The contact information of the volunteers was collected at the end of the 
session and an appointment was made through the group’s coordinator. 
 
Data Collection: 
Subjects who were recruited through E-week, flyers, and DI ads were faculty, staff and students 
associated with the University of Illinois at Urbana-Champaign. These individuals were 
examined in Bevier Hall room 199. Participants from the Senior High Rise DM Outreach groups 
were visited at the same sites of CUPHD as recruitment. All the testing was conducted between 
September 2009 and May 2010. 
Subjects were provided the email address of the student researcher in all recruitment methods. 
An appointment for participation in the study was scheduled upon their contact with the student 
researcher. An email with the exam instructions on the bone mass density test, anthropometric 
measurements, the health questionnaire and DNA testing as well as the reimbursements were 
then sent to the potential participant. Those who were unable to currently participate due to their 
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busy schedules or those who were unable to attend their appointment were asked if and when 
they could be contacted again for rescheduling an appointment. A reminder email was also sent 
to the participant one day before their exam appointment with detailed information about 
direction to the study location, parking and instructions about refraining from eating food, 
drinking beverages (including water), smoking, brushing teeth, and chewing gum for an hour 
before the appointment, provided they were interested in participating in the DNA testing. 
Study approval was obtained from the Institutional Review Board at the University of Illinois at 
Urbana-Champaign. Participants were provided two written informed consent forms approved by 
the IRB at the time of enrollment. The first consent form included information on bone screening 
in those with diabetes and informed the participants of the research protocol, including the heel 
ultrasound device and bone mass density measurement, as well as the anthropometric 
measurements and the brief health questionnaire. The second consent form provided information 
about DNA testing and saliva collection. It was explained to the subject that participation in this 
second part of the study was completely optional. Both consent forms informed the participants 
of their rights as human subjects, including their right to withdraw from the study at any time, 
and confidentiality and anonymity of the information. Subjects were asked to sign the consent 
forms prior to participation (See Appendix D for consent forms). 
At the beginning of the study, the participant was given a screening test consisted of three 
questions. The recruiter determined whether the participant was eligible to participate based on 
their answers to these questions. Eligibility was defined as having type 1 or 2 diabetes or pre-
diabetes, not having any pins or metals in the feet/ankles and not having any swelling in the 
feet/ankles. Diabetes was self-reported by the subjects. No examination was conducted to 
diagnose diabetes in the subjects and no proof of the disease was obtained. In case a subject had 
39 
 
either pins/metals or swelling in the foot/ankle, the other foot was used for the bone screening 
test (See Appendix E for the screening test).  
The main part of the exam consisted of subjects rotating through four testing areas; 
anthropometric measurements, self-administered health questionnaire, heel ultrasound testing, 
and saliva collection. Participants had anthropometric measurements taken including weight, 
height, wrist, waist and hip circumferences. A calibrated medical electronic scale and a standard 
stadiometer with a sliding head piece were used for weight and height measurements, 
respectively. Subjects were wearing light clothing and no shoes at the time of measurements. 
Wrist, waist and hip circumferences were taken with a plastic tape measure. Wrist circumference 
was measured around the styloid process of ulna and radius, also known as the “wrist bone”; 
waist circumference was taken at the umbilical level, the midpoint between the lower ridge of the 
ribs and the upper ridge of the pelvis; and hip circumference was measured at the widest area 
around the buttocks. Each measurement was taken three times for precision and was converted 
into metric units (kilograms for weight and centimeters for height and circumferences). Body 
Mass Index (BMI), frame size and Waist-to-hip ratio (WHR) were calculated and recorded based 
on the above-mentioned measurements. The average of the three BMI and WHR measurements 
were used for further analysis. 
The self-administered health questionnaire was designed specifically to gather information about 
diabetes and bone health (See Appendix F). The first section of the questionnaire collected 
demographic information, including gender, date of birth, ethnicity, and education level. Age 
was calculated as the difference between the date of birth and the date of the exam expressed in 
years. The second section assessed the diabetes status, including type of diabetes, duration of 
diabetes, oral medications and insulin use, history of previous diabetes medications, and 
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Hemoglobin A1C (HbA1c) testing, as well as health behaviors and lifestyles, including smoking, 
alcohol use, caffeine intake, calcium/vitamin D supplement use and vegetarianism.   
The third section of the questionnaire was designed to assess the physical activity of the 
participants, including vigorous and moderate physical activity as well as walking and sitting 
habits, all of which were specifically described and explained with examples. Vigorous physical 
activity was defined as taking hard physical effort and making breathing much harder than 
normal, including heavy lifting, digging, aerobics, or fast bicycling. Moderate physical activity 
was described as those activities that take moderate physical effort which make breathing 
somewhat harder than normal, and may include carrying light loads, bicycling at a regular pace, 
or doubles tennis. Walking included at work and at home, walking to travel from place to place, 
and any other walking that was done solely for recreation, sport, exercise, or leisure. Sitting was 
described as any time spent sitting at work, at home, while doing course work, and during leisure 
time, and included time spent sitting at a desk, visiting friends, reading or sitting or lying down 
to watch television. Participants were asked to report how many days and how much time in a 
day they had usually spent in each specific category in the last 7 days for at least 10 minutes at a 
time.  
A history of weight gain and/or weight loss, fall, bone fracture and bone mineral density scan 
was also obtained. A major part of the questionnaire assessed the current status and/or history of 
several medical conditions including thyroid disease; intake of bone medications specifically 
prescribed for bone health; and other medications including antidepressants and glucocorticoids 
that could have an impact on bone density. Information on the family history of participants, 
including diabetes, osteoporosis, bone fracture, loss of height as grown older, high blood 
pressure, and dyslipidemia was also obtained. 
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The last section of the questionnaire was specifically designed to gather information on the 
female reproductive history, including menopause status, age at menopause, Hormone 
Replacement Therapy use, and history of oophorectomy, pregnancy and breastfeeding. 
 
Quantitative Ultrasound (QUS): 
Bone mineral density (g/cm2) in heels was measured on all participants by QUS using Hologic 
Sahara Clinical Bone Sonometer (Hologic Inc., Waltham, MA, 1998). There are no known 
adverse effects from ultrasound testing. Heel BMD was measured with the participant seated in a 
stationary, straight-back chair with their shoes and socks off. The non-dominant foot was used 
for measurement, unless there were pins, metals or swelling in that foot. The participant’s bare 
heel was then covered with a small coating of ultrasound conduction gel and was placed into the 
ultrasound machine in between the already gelled transducer pads with the middle of the heel 
snug against the center of the positioning contour and the positioning line aligned with the gap 
between the patient’s second and third toe. The foot was then held still with the positioning aid 
strapped around the leg. The measurement was taken three times and the average was used for 
further analysis. 
Participants were provided with a copy of their ultrasound results at the end of the testing (See 
Appendix G). Those with T-scores of more than one standard deviation below the mean were 
encouraged to visit their primary physician for further osteoporosis evaluation.  
Quality control was performed using QC phantom each day at the beginning of the testing 
session to monitor system performance. Additionally, a pilot study was conducted to measure the 
precision (percent coefficient of variation) of repeated heel BMD measurements in humans. This 
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was done to ensure that the estimated coefficient of variation specified in the QUS manual was 
correctly obtained in the study. The precision was determined using three measurements of heel 
BMD from three staff volunteers as well as the student researcher and was calculated using SAS 
9.2 software (SAS Inc., 2010). The coefficient of variation was 3%, and was in agreement with 
the reported percentage in the manual. 
At the end of the rotations, willing participants were asked to spit into a vial for their saliva 
sample. Saliva samples were collected according to the manufacture’s protocol and stored 
immediately at -80 °C freezer until the DNA extraction protocol was performed (See Appendix 
H for the genetic study). 
As compensation for participation, subjects received one $5 gift card for participation in the bone 
screening test and another $5 gift card for DNA testing, a recipe book on bone health or diabetes, 
and the opportunity to attend a class or seminar on diabetes and bone health. Participants were 
also provided with a copy of their heel ultrasound results. Subjects who were recruited from the 
University of Illinois were given gift cards to Bevier or Bevier II café, while participants at 
CUPHD were granted either a County Market or Jerry’s IGA gift card, depending on the store 
accessibility at the site of recruitment. 
 
Statistical Analysis: 
The statistical analysis was performed using SAS 9.2 software (SAS Inc., 2010). Power analysis 
and sample size calculation were conducted with SAS power and sample size 3.1 (SAS Inc., 
2010). All the collected data were manually entered into Excel and were double checked by the 
Primary Investigator. 
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Of the continuous variables, all bone health variables including BMD, Tscore, BUA, QUI, and 
SOS were normally distributed. Age, in years, also had a normal distribution. BMI, WHR, 
duration of diabetes in years, length of medication intake, and HbA1c value were not normally 
distributed. For showing the frequency of normal variables, mean ± standard deviation was used, 
whereas for non-normal variables frequency was shown by using median, lower quartile (25th 
percentile), and upper quartile (75th percentile). Two-sample independent t-test and ANOVA test 
were used for the analysis of normal variables, including the association of Type of diabetes with 
age and all the bone health variables. Kruskal-Wallis test was used to compare non-normally 
distributed variables, including the association of Type of diabetes with BMI, WHR, duration of 
diabetes in years, length of medication intake, and HbA1c value. ANOVA with Fisher Least 
Squared Differences (LSD) was used to determine post-hoc mean separation for variables 
identified as statistically significant. Chi-square test was used to look at the associations between 
categorical variables. Pearson correlations were used to assess the correlation between 
continuous normally distributed variables, whereas Spearman correlations were used to assess 
the correlation between continuous non-normally distributed variables. To explain the variance 
in BMD as the dependent variable, stepwise multiple regression analysis was performed. 
Dummy variables were created for the independent categorical variables in the model. P-values 
were set at alpha = 0.05 for statistical significance. 
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CHAPTER 3 
RESULTS 
 
Overall, 54 subjects with pre-, type 1 and type 2 diabetes participated in the study. Table 1 shows 
some of the demographic and anthropometric characteristics of the participants. Age ranged from 
27 to 86 years with a mean of 62 years, and diabetes duration ranged from 1 month to 50 years 
with a median of 7 years. Individuals with type 1 diabetes had higher duration of diabetes and 
lower waist-to-hip ratio. There were no statistical differences in age, medication duration, 
hemoglobin A1C, or BMI across the three diabetic groups. 
Demographic characteristics are presented in Table 2 and diabetes status is shown in Table 3. 
The majority of participants were white/Caucasian women with college/professional degree, who 
had type 2 diabetes, were not on insulin and had diabetes for 7 or more years. Insulin use was 
higher among individuals with type 1 diabetes and those with type 1 diabetes were more likely to 
have diabetes for a longer time. 
Figure 1 shows a pie chart of the frequency of current oral antidiabetic medication use. The 
majority of the participants (34.5%) were not on any type of oral medication. Of those who used 
oral medication, approximately 32.6% were on metformin, followed by 14.3% on a combination 
of metformin and sulfonylurea, and 12.2% on sulfonylureas only.  
Health behaviors and lifestyles are presented in Table 4. The majority of participants were non-
smokers, not regular alcohol users, not vegetarians or vegans, and were on calcium/vitamin D 
supplements. Regular alcohol use was higher in individuals with type 1 diabetes. 
Calcium/vitamin D supplement use was higher among those with type 2 diabetes. 
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Table 5 shows history of weight, falling and bone fracture in participants. Most of the subjects 
did not have a history of weight gain or weight loss of more than 15 lbs in the last year and had 
not experienced falling in the last 6 months. The majority of participants did not have a bone 
fracture during their adult life (21 years or older) and had not experienced a bone mineral density 
scan of whole body or hip/spine. There were no statistical differences in either of the variables 
across the three groups of type of diabetes. 
The QUS bone sonometer was used to measure bone mineral density of the non-dominant heel, 
and results are presented in Table 6. Of the total 54 subjects, bone health variables of 52 
participants were recorded. Four invalid bone mass values were measured for one of the subjects 
due to swollen ankles on both feet, and invalid measurements were recorded 8 times (4 times on 
each foot) from another participant due to the presence of rod in the non-dominant calf. All bone 
health variables were lower in subjects with type 1 diabetes compared to those with type 2 
diabetes, but no statistical differences were found across the three diabetic groups in terms of 
BMD, T-score, quantitative ultrasound index (QUI), broadband ultrasound attenuation (BUA), or 
speed of sound (SOS). Power analysis showed that for a two-sample pooled t test of a normal 
mean difference with a two-sided significance level of 0.05, assuming a common standard 
deviation of 0.1, group sample sizes of 8 (type 1 diabetes) and 38 (type 2 diabetes) did not have 
enough power to detect a difference between BMD means (power=71%). 
T-score values ranged from -4.00 to 2.23 with a mean of -0.76. Approximately 44.2% of the 
participants had T-scores smaller than one standard deviation below the young adult reference 
mean (T-score ≤ -1). Of those with T-scores less than one standard deviation below the reference 
mean, approximately 83% were female, 18% had type 1 diabetes, 32% were on insulin, and 
62.5% had diabetes for 7 or more years (median value) (Table 7). Additionally, of those with T-
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scores less than -2.5 standard deviation threshold for osteoporosis (4 individuals, 7.7% of total 
participants), approximately 75% were female, 25% had type 1 diabetes, and none were on 
insulin (Table 7). On the other hand, 23 postmenopausal white women participated in this study, 
among which approximately 61% had T-scores less than one standard deviation below the 
reference mean, and 13% had T-scores less than -2.5 standard deviation threshold for 
osteoporosis (data not shown). 
Data for the bone mineral density values in various groups, including those for demographics, 
diabetes status, bone health, medical conditions, and female reproductive history are presented in 
Tables 8 and 9. No statistical differences were found for BMD values within gender, insulin use, 
duration of diabetes, medication type, history of falling and bone fracture. Power analysis 
showed that for a normal mean difference with a two-sided significance level of 0.05, assuming a 
common standard deviation of 0.1, group sample sizes of 18 (duration <7 years) and 18 (duration 
≥ 7 years) have a power of 82% to detect a difference between BMD means, and group sample 
sizes of 37 (Non-insulin users) and 14 (Insulin users) have a power of 88% to detect a difference 
between BMD means. The power for detecting significant differences between BMD means for 
gender, history of falling and bone fracture were not strong enough (power < 80%). 
However, of all the conditions and diseases, BMD values were only significantly lower among 
subjects with a current status and/or history of cancer compared to those who never experienced 
cancer (p=0.037). Of all the medications, significant lower BMD values were only found in those 
who currently used or had a history of using any of the bone medications compared to 
individuals who were never on any of the bone meds (p=0.003). Least Significant Difference to 
determine post hoc significance showed that in females, those who had undergone menopause 
had significantly lower BMD values than those who had not experienced menopause yet 
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(p=0.0033). Power analysis for a normal mean difference with a two-sided significance level of 
0.05, assuming a common standard deviation of 0.1 for cancer, bone medication, and menopause 
were all above 80% to detect a statistical significant difference between BMD means.  
Of those variables for medications and diseases which did not have a statistical significant 
relationship with BMD values, power analysis for a normal mean difference with a two-sided 
significance level of 0.05, assuming a common standard deviation of 0.1 for hypertension, 
thyroid disease and kidney problems were 92%, 86%, and 86%, respectively, to detect a 
difference between BMD means. Of all the medications for which no significant relationship was 
reported, only power analysis at significance level of 0.05 for thyroid medication and Actonel as 
a bone medication were strong enough to detect a difference between BMD means (86% and 
90%, respectively). Additionally, only power analysis with a two-sided significance level of 0.05 
for family histories of diabetes, hypertension and bone fracture were above the 80% threshold of 
detecting significant differences between BMD means (85%, 83%, and 81%, respectively).. 
Physical activity is shown in Table 10. Approximately 83% of the participants had some kind of 
physical activity, either vigorous, moderate, or walking during the last 7 days of their data 
collection, and 7.55% spent absolutely no time on physical activity. Statistical significant 
differences were found between BMD values of those with and without moderate physical 
activity and those not sure about their moderate physical activity (p=0.048). Least Significant 
Difference to determine post hoc significance showed that individuals who had moderate 
physical activity in the past 7 days had significantly higher BMD values than those who did not 
have any moderate physical activity or those who were not sure about their moderate activity. 
Power analysis for a normal mean difference with a two-sided significance level of 0.05, 
assuming a common standard deviation of 0.1 for moderate physical activity yielded a power of 
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80% for detecting significant differences between BMD means. For all other physical activity 
levels that were not significantly related to BMD values, the power analysis for detecting 
significant differences between BMD means did not yield strong enough powers (power < 80%). 
Table 11 illustrates the odds ratio for BMD and T-scores among subjects with type 2 and pre-
diabetes against individuals with type 1 diabetes (used as the reference group). BMD values were 
higher among participants with type 2 diabetes than those with type 1 diabetes and pre-diabetes, 
but the difference was not statistically significant. The odds ratio for high BMD values in the 
group with type 2 diabetes and pre-diabetes compared to type 1 diabetes was 14.54 and 2.31, 
respectively. That is, for a one standard deviation increase in BMD value, the odds of having 
type 2 diabetes and pre-diabetes increased by 1354% [95% CI: 4.916-43.027] and 131% [95% 
CI: 0.513-10.381], respectively. In other words, the odds of high BMD values for type 2 diabetes 
was about 1354% of the odds for type 1 diabetes, and the odds of high BMD values for pre-
diabetes was about 131% of the odds for type 1 diabetes. On the contrary, the odds of high BMD 
values for type 1 diabetes was only about 0.069 times of the odds for type 2 diabetes (95% CI: 
0.023-0.203; data not shown). 
After adjustment for BMI, the odds of high BMD values for type 2 diabetes increased from 14.54 
to 28.96 times greater than type 1 diabetes, but the odds ratio for pre-diabetes compared to type 1 
diabetes decreased from 2.31 to 1.17 times (Table 11). Additionally, when adjusted for BMI, the 
odds ratio for high BMD values in subjects with type 1 diabetes significantly decreased from 
0.069 to 0.035 times of the odds in individuals with type 2 diabetes (95% CI: 0.011-0.107; data 
not shown). Adjustment for age or gender did not yield statistically different results and the odds 
ratio and confidence intervals across all three diabetic groups were non-estimable (data not 
shown). 
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In addition, low BMD was categorized as those with T-scores below one standard deviation of 
the reference mean (T-score < -1) and was compared against the control group with normal 
BMD who had T-scores greater than one standard deviation below the reference mean (T-score > 
-1). We found that type of diabetes was not associated with low T-scores. The odds ratio for low 
BMD in type 2 diabetes and pre-diabetes compared to type 1 diabetes was 0.818 and 1.000, 
respectively. In other words,  the odds of low BMD values for type 2 diabetes was about 82% of 
the odds for type 1 diabetes, and the odds of low BMD values for pre-diabetes was exactly the 
same as the odds for type 1 diabetes. On the other hand, the odds of low BMD values was 1.22 
times greater in individuals with type 1 diabetes than those with type 2 diabetes (95% CI: 0.267-
5.585; data not shown). Adjustment for age did not change the results, and adjustment for BMI 
yielded non-estimable odds ratio and confidence intervals across all groups (data not shown). 
The correlations of demographic, anthropometric and diabetes factors are presented in Table 12. 
Only age had a moderate negative association with BMD (r=-0.574; p<0.0001). This association 
was significantly stronger among type 1 and type 2 diabetes (r=-0.742,-0.673, respectively; 
p<0.0001), but not in pre-diabetes (r=-0.400; p=0.60; data not shown). All other variables had 
weak associations with BMD and lacked statistical significance. These associations were not 
statistically different by diabetes status either (data not shown). 
The unadjusted and adjusted BMD and T-score values across all three diabetic groups are shown 
in Table 13. Participants with type 1 diabetes had lower BMD and T-score values than those with 
type 2 diabetes. With adjustment for age, BMD values became lower in individuals with type 1 
diabetes (mean=0.40), however, they were not statistically different in subjects with type 2 and 
pre-diabetes. After adjustment, T-score levels became lower in type 1 diabetes and higher in type 
2 diabetes (mean=-1.09, -0.59, respectively). T-score values did not show any statistical change 
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in pre-diabetes. Adjustment for BMI did not yield any statistical differences in either BMD or T-
scores (data not shown). 
Multiple regression equations were calculated for bone mineral density (BMD) as the dependent 
variable against independent variables in several categories: demographics, diabetes status, 
diabetes care and management, lifestyle and health behaviors, bone health status, oral 
medications, current status and/or history of medical conditions, family history, and female 
reproductive history. The equations are presented in Table 14. In terms of demographics, gender 
and African-American/black ethnicity contributed to the variance in BMD. Among variables for 
diabetes status, age, type 1 diabetes and oral metformin use were contributors to BMD variance. 
Duration of diabetes and the most current HbA1c value contributed to BMD variance in the 
category of diabetes care and management. In terms of lifestyle and health behaviors, 
consumption of calcium/vitamin D supplements as well as moderate physical activity during the 
last 7 days including those activities that take moderate physical effort which make breathing 
somewhat harder than normal contributed to the variance in BMD. Among variables describing 
the bone health status, only a history of BMD scan had an effect in the variance of BMD. Intake 
of any bone medication specifically prescribed for bone health and current status and/or history 
of osteoporosis separately contributed to the variance in BMD. In terms of family history, family 
history of osteoporosis and loss of height with aging contributed to BMD variance. Among 
variables for female reproductive history, menopause and breastfeeding were significant 
contributors to variance in bone mineral density. 
An overall regression model was calculated for variables which had statistical significance in 
their multiple regression equations. Bone mineral density was used as the dependent variable. 
This model shows that African-American ethnicity, calcium/vitamin D supplement use, family 
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history of loss of height, current status and/or history of osteoporosis, and menopause in female 
significantly contribute to the variance in BMD. The R-square for this model was 0.7714, 
meaning that approximately 77% of the variability of BMD was accounted for by the variables in 
the model (data not shown). On the other hand, the adjusted R-square (0.6953) indicated that 
about 69% of the variability of BMD was accounted for by the model, even after taking into 
account the number of predictor variables in the model (data not shown).  
The coefficients for each of the variables indicated the amount of change in BMD given a one-
unit change in the value of that variable, given that all other variables in the model were held 
constant. Based on the overall model, we would expect a decrease of 0.222 in the BMD value for 
every one-unit increase in African-American ethnicity, a decrease of 0.082 for every one-unit 
increase in calcium/vitamin D supplement intake, a 0.111 decrease for every one-unit increase in 
family history of loss of height, a 0.181 decrease for every one-unit increase in current status 
and/or history of osteoporosis and a decrease of 0.101 for every one-unit increase in menopause, 
assuming that in each case all other variables in the model are held constant.   
In order to compare the strength of the coefficients of these variables, we obtained standardized 
values, also called beta coefficients. These beta coefficients can be used to compare the relative 
strength of the various predictors within the model. Because these standardized coefficients are 
all in the same standardized units, i.e. standard deviation, they can be compared to assess the 
relative strength of each of the predictors. In our overall model, African-American ethnicity had 
the largest beta coefficient, -0.44, and intake of calcium/vitamin D supplement had the smallest 
beta, 0.278.  Thus, a one standard deviation increase in African-American ethnicity led to a 0.44 
standard deviation decrease in predicted BMD, with the other variables held constant. 
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Additionally, a one standard deviation decrease in calcium/vitamin D supplement use resulted in 
a 0.278 standard deviation increase in BMD with all other variables in the model held constant. 
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CHAPTER 4 
DISCUSSION 
 
Bone mineral density was low in our sample of individuals with type 1 diabetes compared to 
those with type 2 diabetes, but this difference lacked statistical significance. Calculating odds 
ratio for BMD showed odds of high BMD values of about 14.5 times greater in subjects with 
type 2 diabetes than those with type 1 diabetes. After adjustment for BMI, the odds of high BMD 
values associated with type 2 diabetes increased to 28.96. On the other hand, adjusting for age 
resulted in lower BMD and T-score values in individuals with type 1 diabetes as well as higher 
T-scores in those with type 2 diabetes. These findings are in agreement with numerous earlier 
studies that have investigated BMD by diabetes status. There is relatively strong evidence to 
suggest that type 1 diabetes has negative impacts on bone health, specifically bone mineral 
density, and that it results in higher incidence of bone fractures. On the other hand, there seems 
to be more discrepancy in skeletal effects of type 2 diabetes. While many studies have shown 
normal to high BMD values in individuals with type 2 diabetes, some have found low BMD 
values.  
Of the most recent studies, Mastrandrea et al in 2008 measured bone mineral density using dual-
energy X-ray absorptiometry on 63 young female subjects with type 1 diabetes aged 13-35 years. 
The results of the study showed a significant reduction in BMD at hip, femoral neck and the 
whole body in women aged 20 years and older. Thus, it was suggested that low BMD as well as 
failure to accumulate bone density after age 20 may contribute to the increased incidence of 
osteoporotic hip fractures in postmenopausal women with type 1 diabetes. (Mastrandrea et al, 
2008). Another study by Hamilton and colleagues in 2009 on both males and females with type 1 
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diabetes aged 20-71 years reported lower BMD values at hip, femoral neck and spine in diabetic 
adult male participants. However, no significant differences were found in BMD values of 
diabetic female subjects compared to their age-matched controls. These results suggested that 
reduced bone density in male could be a result of type 1 diabetes (Hamilton et al, 2009). 
The study by Soto and colleagues in 2011 on young adolescents and adult women with Type 1 
diabetes was conducted with the objective of examining the relationship between bone mass 
density and sex steroids. Diminished bone mass was observed at spine, femoral neck and whole 
body of both the adolescent and adult diabetic women, but there was no association with sex 
steroid levels. It was suggested that the observed decrease in bone mass could be related to 
differences in body composition and age (Soto et al, 2011). 
Unlike type 1 diabetes, the impact of type 2 diabetes on bone health has been shown to be 
conflicting. Some studies have reported protective effects, whereas some others have shown 
negative impact. The exact reason for these conflicting results is unknown, but the inconsistency 
most probably arises from confounding factors such as gender, diabetes complications, body 
mass index (BMI), ethnicity, and pharmacological agents. For instance, in a recent study by Petit 
et al in 2010, higher BMD values were reported in older men aged 65+ years with type 2 
diabetes compared to age-matched healthy controls (Petit et al, 2010). On the contrary to this 
study, Yaturu and colleagues found significantly lower BMD values, as well as increased 
incidences of osteoporosis at hip bone in veteran men with type 2 diabetes compared to age-
matched controls (Yaturu et al, 2009).  
In the present study, hstory of bone fracture during adult life (21 years or older) and history of 
falling in the last 6 months were not statistically different across the diabetic groups in the 
present study. These non-significant observations could possibly be due to the lack of sample 
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size in each category which resulted in a low power unable to detect significant differences of 
BMD values for falling and bone fracture history (power < 80%). These findings are on the 
contrary to the results of previous studies which have reported higher bone fracture risk among 
individuals with type 1 and type 2 diabetes, 
Consistent with the findings on BMD, higher bone fracture risk has been reported in type 1 
diabetes. Various studies have shown increased fracture risk in men and women with type 1 
diabetes (Strotmeyer et al, 2006; Miao et al, 2005; Nicodemus et al, 2001). Previous research has 
shown that a one standard deviation decrease in BMD at the heel, hip or spine of postmenopausal 
women can result in a 1.4-2.6 increased relative risk of bone fracture at any site (Cummings et al, 
2002). In a study by Hofbauer et al in 2007 increases in bone fracture risk at various sites were 
found for type 1 diabetes. These increases ranged from 1-2 folds at the spine to 1.5-2.5 folds at 
the hip bone (Hofbauer et al, 2007). Another supportive evidence was a meta-analysis in 2007 
which reported decreased BMD values and increased hip fracture risk in type 1 diabetes 
(RR=6.94; 95% CI: 3.25-14.78) (Vestergaard, 2007). 
Interestingly, many studies that have shown higher to normal BMD values in type 2 diabetes 
have also reported increased fracture risk. In the meta-analysis by Vestergaard, BMD Z-scores 
were found to be increased in the spine (0.41 ± 0.01) and hip (0.27 ± 0.01) in type 2 diabetes. 
However, hip fracture risk was higher in those with type 2 diabetes (RR=1.38; 95% CI 1.25-
1.53) compared to their age-adjusted controls (Vestergaard, 2007). 
The Rotterdam study, one of the largest studies of its time, reported higher fracture risk in 
patients who had type 2 diabetes for a long time, but not in newly diagnosed subjects (RR=1.69 
and 1.01, respectively) compared to non-diabetic controls (de Leifde et al, 2005). A more recent 
study in Canada confirmed these findings and showed an increase in fracture risk in subjects 
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with type 2 diabetes for more than 5 years compared to the newly diagnosed individuals (Lesli et 
al, 2007). Another supportive evidence is a study by Schwartz et al in 2005 who reported higher 
hip bone loss in older adults with type 2 diabetes (Schwartz et al, 2005).  
All of these findings led to the conclusion that the increase in fracture risk in type 2 diabetes, 
despite high to normal BMD values, could be due to factors other than the bone mineral density. 
One hypothesis is that the stage of type 2 diabetes could be an important determinant, such that 
the initial phase of insulin resistance may have a protective effect on bone, whereas negative 
bone health effects could result from long-term type 2 diabetes (Schwartz, 2009).  
High BMI is a common feature of type 2 diabetes which seems to be accounting for some of the 
increase in BMD values (de Laet et al, 2005). In the present study, we also found higher BMI 
values in individuals with type 2 diabetes compared to subjects with type 1 diabetes, but the 
difference was not statistically significant. Although overweight and obesity have been shown to 
be contributing factors to high BMD values and increased bone fracture risk, previous studies 
have shown the increase in BMD to be persistent even after controlling for BMI (Strotmeyer et 
al, 2004; Rakic et al, 2006; Vestergaard, 2007).  
On the other hand, studies using quantitative computed tomography (QCT) have suggested 
volumetric decreases in cortical bones of individuals with established type 2 diabetes, which due 
to small cortical bone area results in lower compressive bone strength and higher bone fragility 
(Melton et al, 2008; Petit et al, 2010). 
Another hypothesis for increased bone fracture risk in type 2 diabetes could be the long-term 
diabetes complications, including diabetic retinopathy (visual impairments) and peripheral 
neuropathy. Poor vision due to diabetic retinopathy and neuropathy could potentially increase the 
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propensity of the diabetic subject to fall and thus, increase their risk of bone fracture (Rix et al, 
1999; Maurer et al, 2005). Additionally, peripheral neuropathy in type 2 diabetes could lead to 
Charcot osteoarthropathy, defined as bone damage and deformity around weight-bearing joints, 
especially in the foot. This is mostly caused by loss of sensation in the feet due to neuropathy 
which in turn, could result in loss of muscle support, joint instability and bone destruction 
(Hamilton et al, 2009).  
Significant associations for low bone mass density with age and menopause in females have been 
observed in the present study which suggests that menopause and aging have negative effects on 
bone health status and thus, could contribute greatly to the potential adverse effects of type 1 
diabetes on BMD and bone fragility. A study by Danielson et al on postmenopausal women 
reported low BMD values and high bone fracture risk associated with type 1 diabetes. They also 
indicated that women with type 1 diabetes experience aging and menopause-related alterations in 
bone turnover at a younger age which could potentially add to adverse effects of type 1 diabetes 
on bone health status (Danielson et al, 2009).  
With regard to low BMD, defined as T-scores less than one standard deviation below the young 
adult reference mean, about 44% of the participants had low BMD values, who were considered 
to be osteopenic or osteoporotic based on the WHO guidelines (World Health Organization, 
1994). A higher proportion of subjects with type 2 diabetes (73%) met the study criterion for low 
BMD than those with type 1 (18%) or pre-diabetes (9%), however this difference was not 
statistically significant. On the other hand, a smaller proportion of those with low BMD were on 
insulin compared to non-insulin users (33% vs. 68%), and had diabetes for less than 7 years 
compared to those who had diabetes for 7 or more years (37.5% vs. 62.5%), both of which were 
not statistically significant. Additionally, of those with T-scores less than -2.5 standard 
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deviations threshold for osteoporosis, approximately 75% were female, 25% had type 1 diabetes, 
and none were on insulin. 
The statistics for low T-scores in type 1 diabetes observed in the present study is comparable to 
the finding of McCabe in 2007. It was estimated that 50% of those with type 1 diabetes had low 
bone mass density and almost 20% of patients aged 20-56 years had T-scores below -2.5 
standard deviations (McCabe, 2007). Moreover, based on the Third National Health and 
Nutrition Examination Survey (NHANES III, 1988-1991), 34-50% of postmenopausal white 
women have osteopenia, and 17-20% have osteoporosis (Looker et al, 1995). This statistics is 
close to our finding that among the white postmenopausal women, about 61% had T-scores less 
than one standard deviation below the reference mean indicating osteopenia, and 13% had T-
scores below -2.5 standard deviations threshold for osteoporosis. 
In the present study, there was no significant relationship between gender and BMD values, and 
adjustment for gender did not yield significant results for the odds ratio of BMD among subjects 
with type 2 and pre-diabetes against individuals with type 1 diabetes (used as the reference 
group). However, women who had already gone under menopause at the time of the study had 
significantly lower BMD values than women who had not experienced menopause yet. No 
significant associations were found for any of the other female reproductive history variables, 
including hormone replacement therapy. The relationship between gender and bone mineral 
density as well as its influence on the association between diabetes and osteoporosis is still 
controversial. Some studies suggest lower BMD values and in turn, higher bone fracture and 
osteoporosis risk in males than females. In this regard, the use of hormone replacement therapy, 
oral contraceptives, and higher levels of estrogen before menopause in females could be 
contributing to the protective effects on the bone health status (Strotmeyer et al, 2006).  
59 
 
In the present study, the majority of participants who received oral antidiabetic medication, were 
on metformin, followed by a combination of metformin and sulfonylureas, and sulfonylurea 
alone. Oral antidiabetic medications also have direct negative and positive effects on bone health 
status, however, there was no significant relationship between intake of any of these antidiabetic 
medications and BMD. Metformin and sulfonylureas have been shown to increase osteoblast 
proliferation and differentiation by inducing alkaline phosphatase production and function and 
osteocalcin expression, which in turn, reduce the risk of bone fracture in patients undergoing 
treatment (Molinuevo et al, 2010; Ma et al, 2010; Zinman et al, 2010). Metformin acts primarily 
by decreasing hepatic glucose production and also has a minor increase in muscle and adipose 
tissue glucose uptake which may improve insulin resistance. Its major side effects are mostly 
gastrointestinal such as nausea, diarrhea, metallic taste, and possible lactic acidosis. 
Sulfonylureas acts by increasing insulin production in the pancreas, and could cause 
hypoglycemia, weight gain, and hyperinsulinemia as their side effects (American Diabetes 
Association, 2011).  
On the other hand, thiazolidinediones (TZDs) such as rosiglitazone and pioglitazone act as 
agonists of PPARγ. TZDs effect on stimulating PPARγ would increase adipogenic differentiation 
of mesenchymal stem cells and thus, reduce the number of differentiated osteoblasts for bone 
formation (Schwartz, 2008; Adami, 2009; Debiais, 2009). TZDs act through several pathways; 
they can decrease insulin resistance, improve blood glucose levels through stimulation of PPAR-
γ, induce minor decrease in hepatic glucose output, preserve pancreatic β-cell function, and 
decrease vascular inflammation. Their main side effect is minor weight gain of 3-6 lbs and 
edema (American Diabetes Association, 2011). 
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Univariate analysis detected significant associations for low bone mass density with current 
status and/or history of cancer, and moderate physical activity in the past 7 days. It has been 
shown that some types of cancer, including breast cancer and prostate cancer can lead to 
decreased bone mass density and increased bone fracture risk. This is due to the metastasis of the 
cancer cells to the bone, where they disrupt the normal process of bone turnover after they 
colonize and use osteoclasts to attack the bone tissue. This, in turn, results in a breakdown of the 
bone structure and a decrease in bone mineral density (Bendre et al, 2003; Clark et al, 2003). In 
the present study, the type of cancer was not reported. 
Effect of exercise on bone health has been shown in several studies. Physical activity induces a 
mechanical load on the bone which is associated with increased bone mineral density as well as 
bone strength and quality (Singh, 2004). Various studies have shown that impact-loading 
exercise, defined as “exercise involving peak forces of more than three-times the body weight, 
including running, tennis and gymnastics” (Tanaka et al, 1999), is positively related to bone 
mass density (Lima et al, 2001; Nurmi-Lawton et al, 2004; Nikander et al, 2005). This type of 
exercise is very much like the moderate physical activity that was reported to be significantly 
correlated with higher BMD values in our study. We defined moderate physical activity as those 
physical activities that make the person breathe somewhat harder than normal, and that may 
include carrying light loads, bicycling at a regular pace, or doubles tennis.   
This study shows the importance of sufficient sample sizes for detecting significant differences 
in BMD means by type of diabetes. Our power analysis shows that for a two-sample pooled t test 
of a normal mean difference with a two-sided significance level of 0.05, assuming a common 
standard deviation of 0.1, group sample sizes of 8 (type 1 diabetes) and 38 (type 2 diabetes) did 
not have enough power to detect a difference between BMD means (power=71%). However, 
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sample size calculations indicate that a sample size of 11 individuals with type 1 diabetes and 38 
individuals with type 2 diabetes, would yield an 80% power to detect significant differences for 
BMD values by type of diabetes. Moreover, sample size analysis suggests that adding only 5 
male participants to the current male to female ratio would result in the ability to observe 
significant differences for BMD values by gender with a power of 80%. 
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CHAPTER 5 
CONCLUSIONS 
 
This study examined the bone health status and vitamin D receptor gene marker of 54 male and 
female subjects with pre-, type 1 and type 2 diabetes, aged 27 to 86 years. All participants were 
faculty, staff and students from the University of Illinois at Urbana-Champaign, or individuals 
associated with the Senior High Rise DM Outreach groups at Champaign-Urbana Public Health 
Department (CUPHD). Data were collected on anthropometric measurements, bone mineral 
density of the heel by quantitative ultrasound testing, vitamin D receptor genetic marker using 
saliva samples, and information on demographics, diabetes status, lifestyle and health behaviors, 
physical activity, current status and/or history of medical conditions and medication use, family 
history of diseases, and female reproductive history through a self-administered questionnaire.  
The results showed that bone mineral density was low in our sample of individuals with type 1 
diabetes compared to those with type 2 diabetes, but this difference lacked statistical 
significance. Adjusting for age resulted in lower BMD and T-score values in individuals with 
type 1 diabetes as well as higher T-scores in those with type 2 diabetes. Calculating odds ratio 
for BMD showed odds of high BMD values of about 14.5 times greater in subjects with type 2 
diabetes than those with type 1 diabetes, which increased after adjustment for BMI. 
The frequency of low T-scores in type 1 diabetes observed in the present study was comparable 
to the statistics of the Third National Health and Nutrition Examination Survey (NHANES III, 
1988-1991) with 34-50% of postmenopausal white women having osteopenia, and 17-20% 
having osteoporosis. Our results indicated that among the white postmenopausal women, about 
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61% had T-scores less than one standard deviation below the reference mean indicating 
osteopenia, and 13% had T-scores below -2.5 standard deviations threshold for osteoporosis.   
Univariate analysis detected significant negative effects of aging, menopause in females, current 
status and/or history of cancer, and moderate physical activity in the past 7 days on bone health 
status. No significant associations were observed between history of bone fracture during adult 
life (21 years or older) or history of falling in the last 6 months with low BMD values.  
Multiple regression model showed that African-American ethnicity, calcium/vitamin D 
supplement use, family history of loss of height, current status and/or history of osteoporosis, 
and menopause in females were significant predictors of low bone mass density. 
In conclusion, additional research is needed to understand the link between BMD and diabetes 
status. The etiology of altered BMD associated with type of diabetes should be further studied 
through intervention studies. 
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CHAPTER 6 
LIMITATIONS AND FUTURE DIRECTIONS 
 
There were several limitations to our research. First, we did not have enough sample size in 
many categories of the variables and this resulted in observing too many lacks of significance. 
Power analysis for those non-significant relationships confirmed low power for a two-sample 
pooled t test of a normal mean difference with a two-sided significance level of 0.05 to detect 
significant differences of BMD values for many variables included in this study. A further 
sample size calculation suggested that by adding only a couple of more subjects to each category, 
for example by recruiting 5 more males or 3 more individuals with type 1 diabetes, a power of 
80% could be obtained, which is strong enough to detect any significant difference of BMD 
values for potential predictors of low BMD, including gender and type of diabetes. Thus, 
increasing the sample size in future studies even to the minimum numbers required for a power 
of 80% is suggested. 
Another limitation of this study was lack of a control group. There were too many potential 
confounders in this study which we could have adjusted for only by recruiting a control group. 
Selection of an age-matched or gender-matched control group seemed to be a good option, so 
that other potential confounders, including BMI could be matched and adjusted for as well. Thus 
due to the lack of a control group, confounding of the association between diabetes status and 
BMD would possibly be too large. This absence of adjustment for potential confounding 
variables may explain some of the heterogeneity of the results of the present study compared to 
previous studies, as well as limited sample sizes. Therefore, it is recommended to minimize the 
potential effects of confounding variables through the selection of a well-matched control group. 
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The current study sample primarily included white/Caucasian subjects and VDR gene marker 
analysis was only conducted in this ethnic group. Future studies need to be done in various 
ethnic groups including minorities to determine if racial/ethnic differences among individuals 
with diabetes is associated with low BMD values and genetic markers. If significant differences 
do actually exist, prevention and treatment programs for bone health and diabetes status should 
be differentially targeted. 
Another potential limitation is the observational nature of this study which limits the ability of 
the researchers to explain potential etiology of low BMD values associated with type 1 diabetes 
and odds ratio of high BMD levels in individuals with type 2 diabetes. Future studies should be 
designed intervention studies to be able to truly elucidate the long-term effects of bone turnover 
and glycemic control on BMD and fracture risk in individuals with diabetes. 
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TABLES AND FIGURES 
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Figure 1. Frequency of Current Intake of Antidiabetic Medication Type (0: No medication; 1: Metformin; 
2: Sulfonylureas; 6: Metformin + Sulfonylurea; Other: TZD + Sulfonylurea; Metformin + TZD) 
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Table 1. Characteristics of Participants – Total and by Type of Diabetes 
Characteristic Total 
n = 54 
Type 1 
Diabetes 
n = 8 
Type 2 
Diabetes 
n = 40 
Pre-
Diabetes 
n = 4 
Demographic 
 
Age (years) 
 
        
        Range (years) 
 
 
 
61.98 ± 15.661 
(n=51) 
 
27.00 – 86.00 
 
 
53.25 ± 22.38  
(n=8) 
 
 
27.00 – 82.00 
 
 
63.05 ± 13.51 
(n=38) 
 
36.00 – 84.00 
 
 
63.25 ± 15.90  
(n=4) 
 
41.00 – 78.00 
Diabetes Status 
 
Duration of diabetes 
(years) 
 
       Range (years) 
 
Medication duration 
(years) 
 
        Range (years) 
 
HbA1c value (%) 
 
 
7.00; 3.00; 
12.002 (n=41) 
 
 
0.08 – 50.00 
 
7.00; 3.50; 8.00 
(n=9) 
 
0.70 – 13.00 
 
6.80; 6.65; 7.15 
(n=16) 
 
 
20.00; 9.00; 
40.00 (n=7) 
 
 
2.50 – 50.00 
 
13.00; 13.00; 
13.00 (n=1) 
 
- 
 
7.30; 6.80; 
7.80 (n=2) 
 
 
6.25; 3.00; 
10.00 (n=32) 
 
 
0.08 – 21.00 
 
6.25; 3.25; 
7.50 (n=8) 
 
0.70 – 8.00 
 
6.80; 6.50; 
7.10 (n=14) 
 
 
1.37; 0.75; 
2.00 (n=2) 
 
 
0.75 – 2.00 
 
- 
 
 
- 
 
- 
Anthropometrics 
 
BMI 
 
 
WHR 
 
 
31.71; 27.78; 
38.82 (n=53) 
 
 
0.93; 0.88; 0.99 
(n=50) 
 
 
29.45; 24.83; 
32.04 (n=8) 
 
 
0.90; 0.80; 
0.94 (n=7) 
 
 
33.27; 28.31; 
40.67 (n=39) 
 
 
0.93; 0.88; 
0.99 (n=37) 
 
 
30.30; 23.68; 
41.20 (n=4) 
 
 
1.00; 0.89; 
1.24 (n=4) 
 
1
 Mean ± Standard deviation for normal variables 
2
 Median; Lower quartile; Upper quartile for non-normal variables 
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Table 2. Demographic Characteristics - Total and by Type of Diabetes1 
Demographics Total 
n = 54 
Type 1 
Diabetes 
n = 8 
Type 2 
Diabetes 
n = 40 
 
Pre-
Diabetes 
n = 4 
 
Gender 
        Male 
        Female 
 
15 (27.78) 
39 (72.22) 
 
2 (25.00) 
6 (75.00) 
 
11 (27.50) 
29 (72.50) 
 
1 (25.00) 
3 (75.00) 
Ethnicity 
        White/Caucasian 
        African-American 
        Asian/Pacific Islander 
        Latino/Hispanic 
        Native American 
        Mexican-American 
        Other 
 
45 (84.91) 
6 (11.32) 
1 (1.89) 
0 
0 
0 
1 (1.89) 
 
8 (100) 
0 
0 
0 
0 
0 
0 
 
33 (82.50) 
5 (12.50) 
1 (2.50) 
0 
0 
0 
1 (2.50) 
 
3 (75.00) 
1 (25.00) 
0 
0 
0 
0 
0 
Education level 
        Not completed High school 
        High school/GED 
        Some college 
        College/Professional degree 
10 (19.23) 
5 (9.62) 
14 (26.92) 
23 (44.23) 
0 
2 (25.00) 
0 
6 (75.00) 
9 (23.08) 
3 (7.69) 
12 (30.77) 
15 (38.46) 
1 (25.00) 
0 
1 (25.00) 
2 (50.00) 
 
1
 Frequency (Percentage) 
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Table 3. Diabetes Status - Total and by Type of Diabetes1 
Diabetes Status Total 
n = 54 
Type 1 
Diabetes 
n = 8 
Type 2 
Diabetes 
n = 40 
 
Pre-
Diabetes 
n = 4 
 
Diabetes type 
        Type 1 
        Type 2 
        Pre-diabetes 
 
8 (15.38) 
40 (76.92) 
4 (7.69) 
 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
Diabetes duration 
        < 7 years2 
        ≥ 7 years 
 
20 (48.78) 
21 (51.22) 
 
1 (14.29) 
6 (85.71) 
 
17 (53.13) 
15 (46.88) 
 
2 (100) 
0 
Insulin use 
        No 
        Yes 
 
39 (73.58) 
14 (26.42) 
 
1 (12.50) 
7 (87.50) 
 
33 (82.50) 
7 (17.50) 
 
4 (100) 
0 
     
  
1
 Frequency (Percentage) 
     
2 Median value for duration of diabetes 
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Table 4. Health Behaviors and Lifestyles - Total and by Type of Diabetes1 
Health Behaviors and Lifestyles Total 
n = 54 
Type 1 
Diabetes 
n = 8 
Type 2 
Diabetes 
n = 40 
 
Pre-
Diabetes 
n = 4 
 
Regular smoking 
        No 
        Yes         
 
48 (90.57) 
5 (9.43) 
 
6 (75.00) 
2 (25.00) 
 
38 (95.00) 
2 (5.00) 
 
3 (75.00) 
1 (25.00) 
Regular alcohol use 
        No 
        Yes 
 
46 (86.79) 
7 (13.21) 
 
4 (50.00) 
4 (50.00) 
 
38 (95.00) 
2 (5.00) 
 
3 (75.00) 
1 (25.00) 
Calcium/Vitamin D supplement use 
        No 
        Yes 
        Not sure/Don’t know 
 
18 (39.13) 
27 (58.70) 
1 (2.17) 
 
1 (16.67) 
5 (83.33) 
0 
 
17 (48.57) 
17 (48.57) 
1 (2.86) 
 
0 
4 (100) 
0 
Vegetarian/Vegan 
        No 
        Yes  
 
48 (94.12) 
3 (5.88) 
 
7 (100) 
0 
 
36 (92.31) 
3 (7.69) 
 
4 (100) 
0 
     
1
 Frequency (Percentage) 
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Table 5. History of Weight, Falling and Bone Fracture - Total and by Type of Diabetes1 
Weight, Fall and Bone 
Fracture History 
Total 
n = 54 
Type 1 
Diabetes 
n = 8 
Type 2 
Diabetes 
n = 40 
 
Pre-
Diabetes 
n = 4 
 
Weight loss >15 lbs  
        No 
        Yes         
 
40 (75.47) 
13 (24.53) 
 
8 (100) 
0 
 
28 (70.00) 
12 (30.00) 
 
4 (100) 
0 
Weight gain >15 lbs 
        No 
        Yes 
 
43 (87.76) 
6 (12.24) 
 
8 (100) 
0 
 
32 (86.49) 
5 (13.51) 
 
3 (75.00) 
1 (25.00) 
History of falling  
        No 
        Yes         
 
40 (76.92) 
12 (23.08) 
 
7 (87.50) 
1 (12.50) 
 
29 (74.36) 
10 (25.64) 
 
4 (100) 
0 
History of bone Fracture  
        No 
        Yes  
 
32 (61.54) 
20 (38.46) 
 
5 (62.50) 
3 (37.50) 
 
23 (57.50) 
17 (42.50) 
 
3 (100) 
0 
History of BMD scan  
        No 
        Yes 
 
34 (65.38) 
18 (34.62) 
 
5 (62.50) 
3 (37.50) 
 
25 (62.50) 
15 (37.50) 
 
3 (100) 
0 
     
1
 Frequency (Percentage) 
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Table 6. Bone Health Variables - Total and by Type of Diabetes1 
 
Bone 
Health 
Variables 
 
Total 
n = 52 
Type 1 
Diabetes 
n = 8 
Type 2 
Diabetes 
n = 38 
Pre-Diabetes 
n = 4 
 
BMD 
 
 
0.48 ± 0.15 
 
0.43 ± 0.12 
 
0.50 ± 0.17 
 
0.44 ± 0.08 
 
T-score 
 
 
-0.76 ± 1.43 
 
-0.94 ± 1.43 
 
-0.67 ± 1.53 
 
-1.24 ± 0.73 
 
BUA 
 
 
89.09 ± 24.60 
 
81.25 ± 19.29 
 
91.54 ± 26.81 
 
82.25 ± 12.94 
 
QUI 
 
 
70.32 ± 23.42 
 
61.79 ± 18.13 
 
72.45 ± 25.60 
 
65.50 ± 9.90 
 
SOS 
 
 
1537.77 ± 38.66 
 
1529.08 ± 30.43 
 
1540.88 ± 42.34 
 
1527.81 ± 22.91 
    
     
1
 Mean ± Standard deviation 
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Table 7. T-scores Smaller than One Standard Deviation and 2.5 Standard Deviations below the 
Young Adult Reference Mean1 
 
Parameters T-score 
≤ -1 
T-score 
≤ -2.5 
Gender 
         Male 
         Female         
 
4 (17.39) 
19 (82.61) 
 
1 (25) 
3 (75) 
Type of diabetes 
         Type 1 
         Type 2 
         Pre-diabetes 
 
4 (18.18) 
16 (72.73) 
2 (9.09) 
 
1 (25) 
3 (75) 
0  
Insulin 
         No 
         Yes          
 
15 (68.18) 
7 (31.82) 
 
4 (100) 
0 
Duration of diabetes 
         <7 years2 
         ≥ 7 years          
 
6 (37.5) 
10 (62.5) 
 
2 (66.67) 
1 (33.33) 
     
 
1
 Frequency (Percentage) 
          2 Median value for duration of diabetes 
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Table 8. Bone Mineral Density (BMD) by Demographics, Diabetes Status, and Bone Health 
 
Parameters 
 
BMD 
Gender 
         Male 
         Female         
 
0.5448 ± 0.14571 
0.4653 ± 0.1551 
Medication type 
         Metformin 
         Sulfonylurea 
         Metformin + Sulfonylurea 
 
0.5549 (15)2 
0.5515 (6) 
0.4268 (6) 
Insulin 
         No 
         Yes          
 
0.5103 ± 0.1080 
0.4521 ± 0.1490 
Duration of diabetes 
         <7 years3 
         ≥ 7 years          
 
0.5325 ± 0.1559 
0.4719 ± 0.1379 
History of falling  
        No 
        Yes         
 
0.5075 ± 0.1388 
0.4343 ± 0.2051 
History of bone Fracture  
        No 
        Yes  
 
0.5155 ± 0.1426 
0.4383 ± 0.1757 
      
1
 Mean ± Standard deviation 
          2 Mean (Frequency) 
     
3 Median value for duration of diabetes    
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Table 9. Bone Mineral Density (BMD) by Medical Conditions and Female Reproductive 
History1 
 
 
Parameters 
 
BMD P-value2 
Cancer 
         No 
         Yes         
 
0.5140 ± 0.1577 
0.3993 ± 0.1191 
 
0.037* 
Bone medication 
         No 
         Yes 
 
0.5243 ± 0.1590 
0.3507 ± 0.0842 
 
0.003* 
Menopause 
         No 
         Yes          
 
0.5884 ± 0.1317 
0.4214 ± 0.1362 
 
0.0033* 
       
 
1
 Mean ± Standard deviation 
         2
 Independent two-sample t-test; α=0.05 
   
* p<0.05 
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Table 10. Bone Mineral Density (BMD) by Physical Activity1 
 
Physical Activity Total 
n = 54 
BMD 
n = 52 
Vigorous Physical Activity 
         No 
         Yes 
         Not sure/Don’t know 
 
22 (44.00) 
19 (38.00) 
9 (18.00) 
 
0.53 ± 0.15 
0.50 ± 0.14 
0.40 ± 0.15 
Moderate Physical Activity 
         No 
         Yes 
         Not sure/Don’t know 
 
12 (24.49) 
28 (57.14) 
9 (18.37) 
 
0.48 ± 0.14 
0.53 ± 0.15 
0.38 ± 0.14 
Walking 
         No 
         Yes 
         Not sure/Don’t know 
 
7 (13.46) 
38 (73.08) 
7 (13.46) 
 
0.55 ± 0.16 
0.48 ± 0.14 
0.42 ± 0.21 
Total Physical Activity 
         No 
         Yes 
         Not sure/Don’t know 
 
4 (7.55) 
44 (83.02) 
5 (9.43) 
 
0.53 ± 0.21 
0.50 ± 0.14 
0.36 ± 0.15 
Vigorous and Moderate Physical Activity 
         No 
         Yes 
         Not sure/Don’t know 
 
10 (19.61) 
33 (64.71) 
8 (15.69) 
 
0.48 ± 0.16 
0.52 ± 0.14 
0.38 ± 0.15 
     
1
 Mean ± Standard deviation 
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Table 12. Spearman Correlations of Demographic, Anthropometric and Diabetes Status 
Variables with Bone Mineral Density (BMD) 
 
Demographic, Anthropometric and 
Diabetes Factors 
 
Correlation Coefficient P-value 
 
Age (years) 
 
 
-0.574 
 
<0.0001* 
 
Body Mass Index (BMI) 
 
 
0.078 
 
0.5857 
 
Waist-to-Hip Ratio (WHR) 
 
 
-0.001 
 
0.9944 
 
Duration of diabetes (years) 
 
 
-0.174 
 
0.2901 
 
Duration of medication intake (years) 
 
 
0.146 
 
0.4175 
 
HbA1c value (%) 
 
 
0.196 
 
0.2028 
 
*
 p<0.05 
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Table 13. Unadjusted and Adjusted Bone Mineral Density (BMD) and T-score values between 
Type 1, Type 2 and Pre-diabetes1 
Bone 
Health 
Variables 
Unadjusted 
 
Adjusted for Age2 
Type 1 
Diabetes 
 
Type 2 
Diabetes 
 
Pre-
Diabetes 
 
Type 1 
Diabetes 
 
Type 2 
Diabetes 
 
Pre-
Diabetes 
 
BMD 0.43 ± 0.12 0.50 ± 0.17 0.44 ± 0.08 0.40 ± 0.12 0.51 ± 0.17 0.44 ± 0.08 
 
T-score 
 
-0.94 ± 1.43 -0.67 ± 1.53 -1.24 ± 0.73 -1.09 ± 1.43 -0.59 ± 1.53 -1.20 ± 0.73 
    
 
1
 Mean ± Standard deviation 
 2
 Adjusted for Age (as a continuous variable) 
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Table 14. Stepwise Multiple Regression Equations for bone mineral density (BMD) as the 
Dependent Variable 
Category Equation P-value 
Demographics 0.654 – 0.088 [Gender] – 0.145 [African-American]1  0.0334 
Diabetes Status 0.821 – 0.005 [Age] – 0.097 [DMType1]2 + 0.087 
[Metformin] <0.0001 
Diabetes Care and 
Management 0.497 – 0.006 [DMDuration]
3
 – 0.015 [HbA1cvalue] 0.0086 
Lifestyles and Health 
Behaviors 0.485 – 0.081 [Calcium/VitD] + 0.093 [PAmoderate]
4
 
0.0429 
Bone Health Status 0.531 – 0.100 [BMDscan] 0.0447 
Medications5 0.524 – 0.174 [Bonemed]6 0.0030 
Medical Conditions7 0.521 – 0.250 [Osteoporosis] <0.0001 
Family History 0.954 – 0.007 [Age] – 0.209 [FHOsteoporosis]8 – 0.091 
[FHHtloss]9 0.0014 
Female Reproductive 
History 0.548 – 0.143 [Menopause] + 0.093 [Breastfeeding] 0.0032 
Overall Model  0.673 – 0.222 [African-American] – 0.082 [Calcium/VitD] 
– 0.111 [FHHtloss] – 0.181 [Osteoporosis] – 0.101 
[Menopause] 
0.0002 
Overall model with 
standardized values 
0 – 0.440 [African-American] – 0.278 [Calcium/VitD] – 
0.376 [FHHtloss] – 0.359 [Osteoporosis] – 0.339 
[Menopause] 
0.0002 
    
 
1
 African-American/Black Ethnicity 
      
2 DMType1 = Type 1 diabetes 
     
3
 DMDuration = Duration of diabetes 
     
4 PAmoderate = Moderate physical activity during the last 7 days 
     
5 Any medications other than diabetic medications 
      
6 Bonemed = History or current use of any type of bone medication 
     
7 Current status and/or history of medical conditions 
      
8 FHOsteoporosis = Family history of osteoporosis 
    
9 FHHtloss = Family history of loss of height as grown older 
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APPENDIX A 
U OF I E-WEEK RECRUITMENT  
 
Diabetes and bone-health screening study seeks subjects 
 
 If you have diabetes, join a heel ultrasound screening study. Short 
survey, height/weight taken. Receive cookbook, $5 gift card; can 
attend bone/diabetes class TBA, if desired. Option for contributing 
saliva samples for study of overlap between diabetes and bone health 
means additional $5. Contact Ghazal Naseri at naserik1@illinois.edu 
to schedule. 
 
URL: http://fshn.illinois.edu/ 
Karen Marie Chapman-Novakofski - kmc@illinois.edu 
Food Science & Human Nutrition 
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APPENDIX B 
U OF I RECRUITMENT FLYER 
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APPENDIX C 
DAILY ILLINI AD 
 
 
 
 
 
 
 
  
Have diabetes? Join a 
heel ultrasound screening 
study. Receive cookbook, $5 
gift card, attend bone/ diabetes 
class. Option for contributing 
saliva samples for study of 
overlap between diabetes and 
bone health, additional $5. 
Contact Ghazal Naseri at 
naserik1@illinois.edu  
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APPENDIX D 
CONSENT FORMS 
Consent Form 1 
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Consent Form 2 
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APPENDIX E 
SCREENING TEST 
 
Do you have diabetes?     Yes         No 
Do you have any pins or metal in your feet/ankles?     Yes       No 
If yes: 
• Which foot/ankle?      Right        Left        Both 
Do you usually have any swelling of your feet/ankles?     Yes        No 
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APPENDIX F 
QUESTIONNAIRE 
 
Code:                                                                                                              Date: 
 
Please take a few minutes to answer the following survey about yourself. 
 
Gender:     Male       Female 
 
Date of Birth: --------------- 
 
Ethnicity:      White/Caucasian 
                       African-American/Black 
                       Asian or Pacific Islander 
                       Latino/Hispanic 
                       Native American/American Indian/Alaskan Native 
                       Mexican-American 
                       Other: -------------   
 
Education:      Did not complete High school 
                         High school/GED  
                         Some college 
                         College/Professional degree 
 
Diabetes status: 
What type of diabetes have you been diagnosed with?     Type1      Type2     Pre-diabetes 
How long have you had diabetes/pre-diabetes? -------------- 
Are you taking medication now?      Yes         No  
If you take medication now, 
• Do you take insulin?       Yes         No  
• Do you take an oral/injectable medication other than insulin?     Yes       No 
          If yes, circle around all the medication you are taking in the attached chart. Also 
specify the length of time you’ve been taking each. 
List your previous medications related to your diabetes: ---------------------- 
Do you have your Hemoglobin A1C
 
tested regularly?     Yes       No 
• If yes, do you remember when the last time was?      Yes -----------------      No 
 If yes, do you remember what it was? –  Yes -----------------      No 
 
Current status: 
Do you smoke cigarettes regularly?       Yes      No 
• If yes, how many per day? ----------    And for how long? ------------- 
• If no, have you ever smoked cigarettes in your life?       Yes       No 
 If yes, how many per day? --------------     And for how long? ---------------- 
Do you drink alcohol regularly?      Yes       No 
• If yes, how many drinks do you have per day?     1       2        >2 
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Do you have more than 4 cups of coffee or tea per day?      Yes      No 
Do you take Calcium/Vitamin D supplements? ------------------ 
• If yes, how much daily? ---------------- 
Are you a vegetarian/vegan?      Yes       No 
 
Physical activity: 
Now, think about all the vigorous activities which take hard physical effort that you did in the 
last 7 days. Vigorous activities make you breathe much harder than normal and may include 
heavy lifting, digging, aerobics, or fast bicycling. Think only about those physical activities that 
you did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical activities? 
 _____  Days per week      
   Don't Know/Not Sure   
2. How much time did you usually spend doing vigorous physical activities on one of those 
days?  
 __ __  Hours per day  
 __ __ __ Minutes per day        
   Don't Know/Not Sure 
  
            Now think about activities which take moderate physical effort that you did in the last 7 days.  
Moderate physical activities make you breathe somewhat harder than normal and may include 
carrying light loads, bicycling at a regular pace, or doubles tennis.  Do not include walking.  
Again, think about only those physical activities that you did for at least 10 minutes at a time. 
  
3. During the last 7 days, on how many days did you do moderate physical activities? 
 ____ Days per week           
   Don't Know/Not Sure 
4. How much time did you usually spend doing moderate physical activities on one of 
those days? 
 __ __ Hours per day         
 __ __ __ Minutes per day         
             Don't Know/Not Sure   
 
Now think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you might do solely for 
recreation, sport, exercise, or leisure. 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a time? 
____ Days per week    
             Don't Know/Not Sure 
 
 6. How much time did you usually spend walking on one of those days? 
 __ __  Hours per day           
 __ __ __ Minutes per day      
             Don't Know/Not Sure   
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Now think about the time you spent sitting on week days during the last 7 days.  Include time 
spent at work, at home, while doing course work, and during leisure time.  This may include time 
spent sitting at a desk, visiting friends, reading or sitting or lying down to watch television. 
7.         During the last 7 days, how much time did you usually spend sitting on a week day?  
   __ __  Hours per weekday                         
    __ __ __ Minutes per weekday       
                         Don't Know/Not Sure 
 
History: 
Have you lost >15 pounds in the last year?     Yes        No 
Have you gained >15 pounds in the last year?     Yes       No 
 
Have you fallen in the last 6 months or do you fall easily?      Yes       No   
Have you had a bone fracture during your adult life (21 years or older)?     Yes       No  
• If so, what areas were fractured? ------------- 
• What year did you have your fracture(s)? -------------- 
 
Have you ever had a Bone Mineral Density Scan of your whole body or hip/spine performed?     
Yes      No    
• If yes, where was the scan performed ----------------    
                 And in what year(s)? ----------- 
 
The following conditions may have an impact on bone density/diabetes. Check all those you currently 
have or have had a history of. 
             Blood clots                                                  Liver problems                 
             Cancer                                                         Osteopenia                 
             Celiac                                                          Osteoporosis 
 Chronic gastrointestinal disorders              Rheumatoid arthritis   
 Dyslipidemia (Lipid disorders)                   Seizures/Epilepsy 
 High blood pressure                                    Stomach or colon surgery 
 Hyperparathyroidism                                  Thyroid condition 
 Kidney problems                                         None                           
 
The following medications may have an impact on bone density. Check all those you are currently 
taking or have taken for more than 3 months in the past 10 years? 
             Aluminum-containing antacids e.g. Aluminum hydroxide (Alu-Cap) 
             Anticoagulants e.g. Heparin 
             Anticonvulsants e.g. Phenytoin (Dilantin) 
             Antidepressants  
             Chemotherapy drugs 
             Glucocorticoids e.g. Prednisone 
             Loop diuretics e.g. Furosemide, Lasix, … 
             Thyroid medicine e.g. Levo-thyroxin 
             None 
 
The following medications are specifically prescribed for bone health. Check all those you are currently 
taking or have taken before. Also specify for how long you have/had been taking them. 
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             Biphosphonates:     Actonel (Risedronate)   ---------------- 
                                             Boniva (Ibandronate Sodium)  -------------------- 
                                             Didrocal (Etidronate)  ------------------ 
                                             Fosamax (Alendronate)  ---------------- 
                                             Reclast (Zoledronic acid)  ---------------- 
 
             Calcitonin:      Calcimar (Miacalcin)  ---------------- 
                                     Fortical (Calcitonin-Salmon (Recombinant) Nasal)  ---------------- 
 
              PTH:     Forteo (Teriparatide)  ---------------- 
 
              SERMs:     Evista (Raloxifene)  ---------------- 
 
              None 
            
Family history: 
Do you have a family history of: 
• Diabetes:     Yes       No   
• High blood pressure:     Yes        No 
• Dyslipidemia (Lipid disorders):      Yes       No 
• Osteoporosis:      Yes      No  
• Bone fracture:     Yes       No 
• Loss of height as grown older:      Yes       No   
 
Females only: 
Have you gone through menopause?      Yes      No 
• If yes, at what age? -----------  
• Are you taking a Hormone Replacement Therapy now?      Yes       No 
• If no, have you ever taken it before?      Yes       No  
Have you had your ovaries removed before menopause?      Yes      No  
Do you have any children?      Yes        No  
Have you ever breast fed?       Yes       No 
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This sheet might help you identify which kind(s) of medication you take. 
 
Class of Medication  Generic Name  Brand Name  
Sulfonylureas 
(first and second generation)  
Glimepiride  
Glyburide  
Glyburide  
Glyburide  
Chlorpropamide 
Acetohexamide 
Glipizide 
Tolbutamide 
Tolazamide  
Amaryl® 
DiaBeta® 
Glynase® 
Micronase® 
Diabinese® 
Dymelor ® 
Glucotrol® 
Orinase® 
Tolinase®  
Meglitinide  Repaglinide  Prandin®  
Biguanides  Metformin  
Metformin hydrochloride 
Glucophage® 
Glucophage XR ®  
Alpha-glucosidase inhibitors  Acarbose 
Miglitol  
Precose®  
Glyset®  
Thiazolidine-diones  Rosiglitazone    
Pioglitazone 
Troglitazone 
Avandia ® 
Actos ® 
Rezulin ® 
D-Phenylalanine derivatives  Nateglinide  Starlix®  
 
Common Pill Shapes: 
 
Rounded rectangle  
 
Round pill 
 
Diamond pill 
 
Oval pill 
 
Two-tone capsule 
 
Half rounded rectangle 
 
Half round pill 
 
Half diamond pill 
 
Half oval pill 
 
Square pill 
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APPENDIX G 
QUS RESULTS FORM 
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APPENDIX H 
GENETIC STUDY 
INTRODUCTION 
Genetics of Osteoporosis: 
It has been shown in several heritability studies that more than half of the variance in BMD is 
due to genetics (Krall et al, 1993; Gueguen et al, 1995; Slemenda et al, 1996). In general, twin 
studies have reported higher estimates than family studies (Pocock et al, 1987; Seeman et al 
1989; Slemenda et al, 1991), in which generations have been compared. In a study by Arden et 
al, postmenopausal BMD and heel ultrasound were analyzed in relation to hip fracture to 
determine the genetic component of these important risk factors. In this twin study with identical 
and non-identical pairs aged 50 to 70 years, bone density was found to have a strong genetic 
component with estimates of heritability ranging from 0.46 to 0.84 at different sites. Other 
aspects of the heel ultrasound also had major genetic components, which remained significant 
after adjustment for BMD. This study suggested that the importance of family history as a risk 
factor for hip fracture could be explained by a combination of different genetic factors 
influencing the structure and density of bone (Arden et al, 1996). 
Vitamin D regulates bone and calcium homeostasis through Vitamin D receptor (VDR) which 
belongs to a superfamily of nuclear hormone receptors and activates the transcription of target 
genes that are involved in calcium metabolism and bone formation (Walters, 1992; Bunce et al, 
1997; Ferrari et al, 1997). VDR gene has been suggested as a potential candidate gene for 
regulation of genetic susceptibility to osteoporosis (Morrison et al, 1992; Stewart et al, 2000; 
Rizzoli et al, 2001). There are several allelic variants of the VDR gene, including ApaI (allele 
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A/a), BsmI (allele B/b), FokI (allele F/f; also known as allele C/T, which was analyzed in the 
present study) and TaqI (allele T/t) restriction endonucleases, all of which have been associated 
with low BMD and bone loss (Morrison et al, 1994; Ferrari et al, 1995; Graafmans et al, 1997). 
However, the results are conflicting (Lim et al, 1995; Looney et al, 1995; Vandevyver et al, 
1997), which mostly arise from inadequately powered studies, genetic heterogeneity, different 
ethnic groups and gene-environment or gene-gene interactions (Lander et al, 1994; Gennari et al, 
2005; Ralston et al, 2006). 
The frequency of VDR alleles varies greatly by ethnic/racial distribution. The association 
between various allelic variants and BMD has been reported separately in Japanese (Kurabayashi 
et al, 1999; Kikuchi et al, 1999), Italian (Gennari et al, 1998), and Mexican-American 
populations (Tornout et al, 1997). Additionally, the frequency of VDR alleles ‘f’, ‘B’ and ‘t’, 
which are associated with low BMD, have been found to be highest in Caucasians followed by 
Africans and Japanese (Ortiz et al, 1992; Dvornyk et al, 2004).  
Therefore, more studies need to be conducted in order to analyze the association between VDR 
genotypes and BMD in different ethnic groups.  
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Objectives: 
In an effort to examine the vitamin D receptor gene marker of adult men and women with pre-, 
type 1 and type 2 diabetes, we aimed to: 
1. determine the frequency distribution of Vitamin D receptor (VDR) genotypes by  
diabetes status. 
2. determine the relationship between VDR genotype and/or polymorphism with risk of low 
BMD. 
 
Hypotheses: 
1. The frequency of CC and TT genotypes are significantly lower and higher, respectively, 
in individuals with type 1 diabetes with lower BMD values. 
2. Vitamin D receptor genotype and/or polymorphism are significantly associated with an 
increased risk for low BMD. 
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METHODOLOGY 
DNA extraction and PCR: 
Saliva DNA was extracted using the manufacturer’s protocol:  Laboratory Protocol for Manual 
Purification of DNA from 4.0 mL of Oragene® DNA/saliva (DNA Genotek, Ontario, Canada, 
2009). Extracted DNA samples were re-suspended in 1.5 ml TE buffer and quantified using the 
Nanodrop spectrophotometer with an average yield of 112 µg (average 260/280 ratio of 1.78) 
and stored at -20⁰C at their original extracted concentrations. The quality of the DNA samples 
was further assessed through polymerase chain reaction (PCR) and confirmation that a PCR 
product was produced through electrophoresis. 
Two predesigned assays for the single nucleotide polymorphisms, SNPs, (rs1805192 and 
rs1544410) were selected from the Applied Biosystems database available online (Applied 
Biosystems Database, 2011). SNP rs1805192 corresponds to PPARγ gene and SNP rs1544410 
corresponds to the Vitamin D receptor (VDR) gene. Genotyping of the two selected markers was 
carried out using Taqman SNP Genotyping Assays (Applied Biosystems, Foster City, CA, 2006) 
following the manufacturer’s protocol for the dry-down method for the DNA template. Samples 
were prepared by adding 5ng of DNA to the plate and allowing to dry overnight. The master mix 
was added to each well and consisted of 2.5ul Taqman Universal Master Mix, 0.25ul 20x SNP 
genotyping assay probe, and 2.25ul molecular grade water. Initial PCR was performed with a 
7900 Real Time PCR System (Applied Biosystems, Foster City, CA, 2006) with the following 
temperature settings: 95⁰C for 10 minutes and 40 cycles of 92⁰C for 15 seconds and 60⁰C for 
1min. Allelic discrimination was used in the analysis of the samples and genotypes were called 
using the Sequence Detection Systems software (SDS) version 2.4 from Applied Biosystems. 
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SDS software called each genotype with 95% confidence and each assay consisted of six non-
template controls. 
Since PPARγ gene was not polymorphic (all CC alleles), the analysis was not further carried out. 
However, for the VDR gene the FokI polymorphism in exon 2 of the VDR gene was studied. 
This polymorphism is a T-C transition and is recognized by the FokI restriction enzyme. This 
transition results in a different translational initiation codon that creates a shorter version of the 
VDR gene (Ralston et al, 2010). FokI digested the first ATG and yielded the f allele, whereas the 
T to C transition destroyed the FokI site and created the F allele. The FF and ff genotypes are 
also named CC and TT, respectively. The alleles were labeled as CC for homozygous absence 
and TT for homozygous presence of the restriction site. Alleles labeled as CT were 
heterozygous. 
 
Statistical analysis: 
ANOVA test was also used to analyze the covariates in the association between BMD as the 
dependent variable and VDR genotype as the independent variable. Logistic regression was used 
to analyze unadjusted and adjusted odd ratios for BMD and T-scores, as well as for the 
association of low BMD (T-scores ≤ -1) vs. high BMD (T-scores > -1) as the nominal dependent 
variable with independent variables including VDR genotype and VDR polymorphism. P-values 
were set at alpha = 0.05 for statistical significance. 
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RESULTS 
Of the total 54 subjects, 51 individuals agreed to participate in the DNA testing and provided a 
saliva sample. The frequency of VDR alleles and their association with BMD is subject to ethnic 
distribution. In our study, analysis of the VDR genetic marker was done only on the 
Caucasian/White ethnicity group because only the frequency of VDR alleles for this ethnic group 
was available (n = 45).  Table 1 illustrates age, BMI, BMD and T-scores in relation to VDR 
genotypes of CC, CT, and TT (CC = homozygous for absence of restriction site; TT = 
homozygous for presence of restriction site; CT = heterozygous). No significant associations 
were detected for any of the variables (p>0.05). 
Frequency distribution and odds ratio of the three VDR polymorphism genotypes within each of 
the three diabetic groups is presented in Table 2. The total genotype distribution was CC, 0.29 (n 
= 12); CT, 0.42 (n = 17); and TT, 0.29 (n = 12). The data suggested that the VDR genotype did 
not differ significantly between the diabetic groups (p=0.3422, Chi-square = 4.5031, 4 df). 
Genotype distributions in the whole sample and in the three diabetic groups of type 1 diabetes, 
type 2 diabetes and pre-diabetes were in Hardy-Weinberg equilibrium (p=0.267, p=0.445, 
p=0.193, p=0.083, respectively). On the other hand, the frequency of CC genotype was lower in 
individuals with type 1 diabetes (n=2, 25%) than in subjects with type 2 diabetes (n=9, 31%; OR 
= 2.00; 95% CI 0.15–26.18), however this difference was not statistically significant (p>0.05).  
Data on the relationship between bone mineral density (BMD) as the dependent variable and 
VDR genotype as the independent variable, and the effect of covariates such as age, gender, 
BMI, duration of diabetes, type of diabetes, insulin use, and history of bone fracture are shown in 
Table 3. Since the covariance analysis only shows standard errors of the estimates, means ± 
standard errors are shown instead of standard deviations. BMD values were higher in CC 
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genotype than CT and TT genotypes, but the difference was not statistically significant (p>0.05). 
When adjusted for covariates, only age, gender, and duration of diabetes showed significant 
effects on the association between BMD and VDR genotype, but adjusting did not result in the 
relationship to become significant in any of the cases. Neither covariate had significant 
interaction with VDR genotyping.  
Frequency distribution and odds ratio of the three VDR polymorphism genotypes were assessed 
between subjects who had diabetes for less than 7 years (median value) compared to those that 
had diabetes for 7 or more years. Data is presented in Table 4. Genotype distributions in the two 
duration groups were in Hardy-Weinberg equilibrium (p=0.096, p=0.906, respectively). VDR 
genotype did not differ significantly between the two duration groups (p=0.3037, Chi-square = 
2.3832, 2 df). On the other hand, the frequency of CC genotype was higher in individuals with 
more than 7 years of diabetes (n=6, 35%) than in subjects who had diabetes for less than 7 years 
(n=5, 29%; OR = 2.80; 95% CI 0.46-16.93), however this difference was not statistically 
significant (p>0.05).  
Multiple regression analysis of BMD as the dependent variables and VDR genotype, age, gender, 
duration of diabetes, type of diabetes and BMI as the independent variables, showed that only 
age and duration of diabetes contributed significantly to the variance in BMD. VDR genotype 
had no significant contribution. The multiple regression equation is as follows: 
BMD = 0.786 – 0.003 [Age] – 0.004 [Duration] (data not shown; p=0.0025)  
Demographic and clinical data of subjects classified by C-T polymorphism genotypes are shown 
in Table 5. Duration of diabetes was significantly lower in individuals with TT genotype 
compared to those with the CC+CT genotype (p = 0.0162). Additionally, subjects with TT 
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genotype had higher BMI when compared with those with CC+CT genotype, and the p-value 
was close to the significance level (p=0.059). No other statistically significant relationships were 
found. 
Table 6 shows the univariate analysis of VDR polymorphism in the two groups divided by T-
scores into low BMD (T-scores ≤ -1) and high BMD (T-scores > -1). The frequency of TT 
polymorphism (homozygous for presence of restriction site) was higher in the group with low T-
scores, but the difference was not statistically significant. 
In order to find risk factors for the lower values of BMD, a logistic regression analysis was 
conducted using T-score as a dependent nominal variable (Low BMD: T-score ≤ -1 vs. high 
BMD: T-score > -1 as the reference) and those variables which had shown significant statistical 
differences in the multivariate regression analysis by BMD as well as VDR genotype and VDR 
polymorphism (TT/CT+CC) as independent variables. Data is shown in Table 7. Age, duration 
of diabetes and menopause were the only significant independent risk factors for low BMD. 
However, VDR genotype or VDR polymorphism were not associated with an increased risk for 
low BMD (p>0.05). 
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DISCUSSION 
Vitamin D has been known as a regulator of bone and calcium metabolism and homeostasis. The 
active form of vitamin D, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] also functions in regulation 
of target gene expression through a specific receptor, called VDR. VDR is a transcriptional 
activator belonging to a superfamily of steroid receptors and can be found in almost all body 
cells (Soldati et al, 2004). The effects of vitamin D are mediated through transcriptional or 
posttranscriptional modifications of the 1,25(OH)2D3–VDR complex (Soldati et al, 2004). 
The significance of VDR gene has not been clearly elucidated. VDR gene polymorphisms have 
been associated with multiple traits and diseases. In animal models, 1,25(OH)2D3  has been 
shown to have a protective effect against autoimmune diseases (Cantorna et al, 1998). An 
important autoimmune disease that is thought to be genetically determined, at least in part, by 
VDR gene polymorphisms, is type 1 diabetes. In a study by Ban et al on a Japanese population, it 
was found that vitamin D receptor polymorphism has an impact on genetic susceptibility to type 
1 diabetes (Ban et al, 2001). Similar finding was reported in a study by Pani and colleagues in a 
German population (Pani et al, 2000). In a more recent study, Zella and Deluca also showed the 
effectiveness of vitamin D in type 1 diabetes (Zella et al, 2003). Additionally, Ortlepp et al found 
that the VDR genotype and physical activity can predict fasting glucose levels in young healthy 
Caucasian men (Ortlepp et al, 2003). 
In the present study, the total genotype distribution was CC, 0.29 (n = 12); CT, 0.42 (n = 17); 
and TT, 0.29 (n = 12). This is in agreement with the minor allele (TT) frequency (0.28) in 
Caucasians specified by TaqMan® SNP Genotyping Assays (Applied Biosystems, Foster City, 
CA, 2006), which was used for genotyping of the marker. 
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Additionally, we did not find any statistically significant association between VDR genotype and 
bone mass density (BMD). However, several studies have shown that VDR gene polymorphisms 
are associated with BMD and perhaps, influence some determinant of bone metabolism. In a 
study by Mitra et al in 2006 in postmenaopausal Indian women, it was found that the average 
BMD at spine and hip of women with genotypes CC (absence of restriction sites for FokI) was 
more than 10% higher than those with genotypes TT (presence of restriction sites for FokI). This 
finding was significant at both bone sites (p<0.05). Additionally, compared to women with 
osteoporotic bone mass, the frequency of CC genotype was significantly higher in women with 
normal bone mass, whereas genotypes TT was more prevalent in women with osteoporotic bone 
mass (Mitra et al, 2006). 
Similar findings of the effects of polymorphisms in VDR gene on genetic susceptibility to type 1 
diabetes have also been reported in several Caucasian groups, including: German (Pani et al, 
2000), Romanian (Guja et al, 2002), Dalmatian population of South Croatia (Skrabic et al, 2003), 
and French (Taverna et al, 2002).  
On the other hand, a large-scale meta-analysis of the association between VDR alleles with 
BMD and fracture risk conducted by the GENOMOS consortium on 26,000 subjects, no 
relationship was found between FokI polymorphism of VDR gene and either BMD or fracture 
(Ralston et al, 2006). This suggests that allelic variation of VDR does not necessarily play an 
important role in regulation of bone mass density or bone fracture in osteoporosis (Ralston et al, 
2010). 
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CONCLUSION 
In the present study, no statistically significant association was found between VDR genotype 
and bone mass density. When adjusted for covariates, only age, gender, and duration of diabetes 
showed significant effects on the association between BMD and VDR genotype, but adjusting 
did not result in the relationship to become significant. Duration of diabetes was significantly 
lower in individuals with TT genotype compared to those with the CC+CT genotype. 
Additionally, subjects with TT genotype had higher BMI when compared with those with 
CC+CT genotype. In another multiple regression analysis using BMD as the dependent variable, 
age, duration of diabetes and menopause were the only significant independent risk factors for 
low BMD, but VDR genotype or VDR polymorphism were not associated with an increased risk 
for low BMD. 
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Table H.1. Age, Body Mass Index (BMI), Bone Mineral Density (BMD) and T-scores in 
Relation to Vitamin D Receptor (VDR) Genotypes 
 
Parameters 
 
VDR Genotype 
CC 
 
 
VDR Genotype 
CT 
 
 
VDR Genotype 
TT 
 
 
P-
value4 
 
Frequency 
  
 
12 (0.29) 1 
 
17 (0.42) 
 
12 (0.29) 
 
- 
 
Age (years) 
 
 
56.08 ± 18.512 
 
64.93 ± 20.77 
 
60.66 ± 9.55 
 
0.4275 
 
BMI 
 
 
32.18; 29.45; 40.673 
 
29.46; 26.70; 30.88 
 
35.79; 28.33; 46.55 
 
0.0954 
 
BMD 
 
 
0.5419 ± 0.1623 
 
0.4723 ± 0.1896 
 
0.4938 ± 0.1055 
 
0.5390 
 
T-score 
 
 
-0.23 ± 1.48 
 
-0.97 ± 1.69 
 
-0.55 ±  1.10 
 
0.4301 
 
1
 Frequency (Percentage) 
2 Mean ± Standard deviation for normal variables 
3
 Median; Lower quartile; Upper quartile for non-normal variables 
4
 ANOVA test for normal variables; Kruskal-Wallis test for non-normal variables; α=0.05 
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Table H.2. Frequency Distribution and Odds Ratio of Vitamin D Receptor (VDR) 
Polymorphism Genotypes between Diabetic Groups 
VDR 
Genotype 
Total 
n = 45 
Type 1 
Diabetes 
n = 8 
Type 2 
Diabetes 
n = 29 
 
Pre-
Diabetes 
n = 3 
 
Odds 
Ratio2 95% CI
2
 
P-
value3 
 
CC 
 
12 (0.29)1 
 
2 (0.25) 
 
9 (0.31) 
 
1 (0.33) 
 
2.00 
4.09 
1 (Ref) 
 
0.15 – 26.18 
0.40 – 41.66 
 
0.5974 
0.2341 CT 17 (0.42) 5 (0.63) 11 (0.38) 0  
TT 12 (0.29) 1 (0.12) 9 (0.31) 2 (0.67) 
 
1
 Number of individuals (Frequency)  
2 Odds ratio and 95% confidence interval for VDR polymorphism in type 1 vs. type 2 diabetes 
(Ref) 
3
 α=0.05 
All groups were in Hardy-Weinberg equilibrium (P > 0.05) 
CC = homozygous for absence of restriction site 
TT = homozygous for presence of restriction site 
CT = heterozygous 
TT genotype as reference (OR = 1.0) 
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Table H.3. Covariates for the Association between Bone Mineral Density (BMD) as the 
Dependent Variable and Vitamin D Receptor (VDR) Genotype as the Independent Variable1 
VDR Genotype BMD P-value2 
Unadjusted 
       CC 
       CT 
       TT 
 
0.5419 ± 0.0486 
0.4723 ± 0.0391 
0.4938 ± 0.0465 
 
0.5390 
Adjusted for Gender 
 
       CC 
       CT 
       TT 
 
 
0.5668 ± 0.0482 
0.4884 ± 0.0383 
0.5212 ± 0.0466 
 
0.4345* 
Adjusted for Age 
       CC 
       CT 
       TT 
 
0.5255 ± 0.0436 
0.4694 ± 0.0373 
0.4904 ± 0.0414 
 
0.6283* 
Adjusted for Age and Gender 
       CC 
       CT 
       TT 
 
 
0.5458 ± 0.0439 
0.4835 ± 0.0371 
0.5123 ± 0.0421 
 
0.5477* 
Adjusted for Duration of diabetes 
 
       CC 
       CT 
       TT 
 
 
0.5646 ± 0.0439 
0.4985 ± 0.0393 
0.4895 ± 0.0455 
 
0.4206* 
       
1
 Mean ± Standard error 
         2
 ANOVA test  
        
* p<0.05 for the covariate 
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Table H.3. (cont.) 
VDR Genotype BMD P-value2 
Adjusted for BMI 
       CC 
       CT 
       TT 
 
0.5698 ± 0.0496 
0.4786 ± 0.0391 
0.4853 ± 0.0470 
 
0.3171 
Adjusted for Type of diabetes 
 
       CC 
       CT 
       TT 
 
 
0.5025 ± 0.0559 
0.4278 ± 0.0528 
0.4556 ± 0.0529 
 
0.5162 
Adjusted for Insulin 
       CC 
       CT 
       TT 
 
0.5375 ± 0.0528 
0.4695 ± 0.0415 
0.4904 ± 0.0494 
 
0.5654 
Adjusted for Bone fracture 
       CC 
       CT 
       TT 
 
 
0.5306 ± 0.0480 
0.4650 ± 0.0385 
0.4869 ± 0.0457 
 
0.5651 
       
1
 Mean ± Standard error 
         2
 ANOVA test; α=0.05 
        
* p<0.05 for the covariate 
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Table H.4. Frequency Distribution and Odds Ratio of Vitamin D Receptor (VDR) 
Polymorphism Genotypes between Duration of Diabetes Groups1 
VDR 
Genotype 
Duration 
<7 years2 
n = 17 
 
Duration 
≥ 7 years 
n = 17 
 
 
 
Odds Ratio3 
 
 
95% CI3 
 
 
P-value4 
 
CC 
 
5 (0.29) 
 
6 (0.35) 
 
2.80 
3.73 
1 (Ref) 
 
0.46 – 16.93 
0.64 – 21.58 
 
0.2621 
0.1411 CT 5 (0.29) 8 (0.47) 
TT 7 (0.42) 3 (0.18) 
 
1
 Number (Frequency) 
2 Median value 
3 Odds ratio and 95% confidence interval for VDR polymorphism in duration of diabetes of 7 or 
more years vs. less than 7 years (Ref) 
4
 α=0.05 
All groups were in Hardy-Weinberg equilibrium (P > 0.05) 
CC = homozygous for absence of restriction site 
TT = homozygous for presence of restriction site 
CT = heterozygous 
TT genotype as reference (OR = 1.0) 
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Table H.5. Demographic and Clinical Data in Subjects with Vitamin D Receptor (VDR) C-T 
Polymorphism Genotypes 
 
Parameters 
 
VDR 
polymorphism 
TT 
 
 
VDR 
polymorphism 
CC + CT 
 
 
 
P-value4 
Number of subjects 12 (29.3) 1 29 (70.7) - 
Age (years) 60.6 ± 9.5 2 61.0 ± 19.9 0.9442 
Gender (M/F) 3/9 (25/75) 1 10/19 (34.5/65.5) 0.5527 
BMI 35.8; 28.3; 46.5 3 30.0; 27.2; 31.2 0.0593 
BMD 0.493 ± 0.105 0.499 ± 0.179 0.9176 
T-score -0.55 ± 1.11 -0.68 ± 1.63 0.7984 
Type of diabetes (1/2) 1/9 (8/75) 7/20 (25/71) 0.2120 
Duration of diabetes (years) 3.8; 1.0; 7.0 8.5; 3.5; 17.0 0.0162* 
HbA1c value (%) 0; 0; 6.5 6.2; 0; 7.0 0.0931 
Insulin use (No/Yes)  9/3 (75/25) 22/7 (76/24) 0.9534 
Smoking (No/Yes) 11/1 (91.5/8.5) 28/1 (96.5/3.5) 0.5088 
Calcium/Vitamin D use (No/Yes) 4/5 (44.5/55.5) 11/15 (42,58) 0.9111 
Vigorous physical activity (No/Yes) 8/3 (73/27) 13/14 (48/52) 0.1670 
Moderate physical activity (No/Yes) 4/6 (40/60) 9/19 (32/68) 0.6530 
Bone medication use (No/Yes) 10/1 (91/9) 17/7 (71/29) 0.1892 
Osteoporosis (No/Yes) 11/0 (100/0) 23/6 (79/21) 0.1018 
 
1
 Frequency (Percentage) 
2 Mean ± Standard Deviation for normal variables 
3
 Median; Lower Quartile; Upper Quartile for non-normal variables 
4
 ANOVA test for normal variables, Kruskal-Wallis test for non-normal variables; α=0.05 
*
 p<0.05 
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Table H.6. Univariate Analysis of Vitamin D Receptor (VDR) Polymorphism between Two 
Groups Divided by T-scores 
VDR Polymorphism 
(TT/CC+CT) 
 
Low T-score  
(≤ -1) 
n = 16 
 
High T-score  
(> -1) 
n = 24 
 
P-value1 
 
Frequency 
 
8 / 16 
 
4 / 12 
 
0.5731 
Percentage (33 / 67) (25 / 75) 
 
1 Chi-square test; α=0.05 
All groups were in Hardy-Weinberg equilibrium (P > 0.05) 
CC = homozygous for absence of restriction site 
TT = homozygous for presence of restriction site 
CT = heterozygous 
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Table H.7. Odds Ratios and 95% CI of T-score of Bone Mineral Density (BMD) Distribution in 
a Logistic Regression1 
 
Parameters 
 
Odds Ratio  
 
 
95% CI 
 
P-value 
Age 1.05 1.007 – 1.106 0.0233* 
Gender (F vs. M) 2.33 0.53 – 10.27 0.2623 
Diabetes Duration 1.09 0.99 – 1.21 0.0481* 
Type of diabetes (type 1 vs. type 2) 1.909 0.399 – 9.141 0.4609 
Calcium/vitamin D use 2.42 0.62 – 9.43 0.2030 
Family history of loss of height 2.96 0.80 – 10.87 0.1016 
Menopause 6.00 1.50 – 23.99 0.0113* 
VDR Genotype 0.99 0.98 – 1.00 0.5824 
VDR polymorphism (TT/CT+CC) 1.50 0.36 – 6.17 0.5742 
 
*
 p<0.05 
CC = homozygous for absence of restriction site 
TT = homozygous for presence of restriction site 
CT = heterozygous 
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